Trial Outcomes & Findings for Absorb IV Randomized Controlled Trial (NCT NCT02173379)

NCT ID: NCT02173379

Last Updated: 2023-10-30

Results Overview

Target lesion failure (TLF) composite of Cardiac Death, Myocardial Infarction attributable to Target Vessel (TV-MI), or Ischemia-Driven Target Lesion Revascularization (ID-TLR))

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

2604 participants

Primary outcome timeframe

30 days

Results posted on

2023-10-30

Participant Flow

A total of 2604 subjects were randomized at 147 sites between August 15, 2014 and March 31, 2017. The last 5-year follow-up visit occurred on April 06, 2022. The database was then cleaned, and data extraction for the 5-year analysis occurred on July 29, 2022.

The number of All-Cause Mortality will differ from that reported in the Participant Flow module. This is due to the follow-up window 'treatment' of the data. Only deaths that occurred prior to the beginning of the 5-year visit window (Day 1797=1825-28) are counted in the Participant Flow; whereas in the AE table, participants who died within the follow-up window are counted.

Participant milestones

Participant milestones
Measure
Absorb BVS
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System
XIENCE
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Overall Study
STARTED
1296
1308
Overall Study
COMPLETED
1099
1118
Overall Study
NOT COMPLETED
197
190

Reasons for withdrawal

Reasons for withdrawal
Measure
Absorb BVS
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System
XIENCE
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Overall Study
Lost to Follow-up
89
81
Overall Study
Withdrawal by Subject
24
29
Overall Study
Physician Decision
8
8
Overall Study
Death
75
72
Overall Study
Other Reason
1
0

Baseline Characteristics

The number of participants analyzed includes subjects who were available at that time of analysis

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Absorb BVS
n=1296 Participants
Subjects receiving public) Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System
XIENCE
n=1308 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Total
n=2604 Participants
Total of all reporting groups
Age, Continuous
63.1 years
STANDARD_DEVIATION 10.1 • n=1296 Participants
62.2 years
STANDARD_DEVIATION 10.3 • n=1308 Participants
62.65 years
STANDARD_DEVIATION 10.2 • n=2604 Participants
Sex: Female, Male
Female
369 Participants
n=1296 Participants
361 Participants
n=1308 Participants
730 Participants
n=2604 Participants
Sex: Female, Male
Male
927 Participants
n=1296 Participants
947 Participants
n=1308 Participants
1874 Participants
n=2604 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
40 Participants
n=1296 Participants
29 Participants
n=1308 Participants
69 Participants
n=2604 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
0 Participants
n=1296 Participants
0 Participants
n=1308 Participants
0 Participants
n=2604 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
1256 Participants
n=1296 Participants
1279 Participants
n=1308 Participants
2535 Participants
n=2604 Participants
Race (NIH/OMB)
American Indian or Alaska Native
4 Participants
n=1296 Participants
8 Participants
n=1308 Participants
12 Participants
n=2604 Participants
Race (NIH/OMB)
Asian
30 Participants
n=1296 Participants
36 Participants
n=1308 Participants
66 Participants
n=2604 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
11 Participants
n=1296 Participants
4 Participants
n=1308 Participants
15 Participants
n=2604 Participants
Race (NIH/OMB)
Black or African American
71 Participants
n=1296 Participants
61 Participants
n=1308 Participants
132 Participants
n=2604 Participants
Race (NIH/OMB)
White
1135 Participants
n=1296 Participants
1160 Participants
n=1308 Participants
2295 Participants
n=2604 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=1296 Participants
0 Participants
n=1308 Participants
0 Participants
n=2604 Participants
Race (NIH/OMB)
Unknown or Not Reported
45 Participants
n=1296 Participants
39 Participants
n=1308 Participants
84 Participants
n=2604 Participants
Region of Enrollment
Canada
28 participants
n=1296 Participants
26 participants
n=1308 Participants
54 participants
n=2604 Participants
Region of Enrollment
United States
1021 participants
n=1296 Participants
1041 participants
n=1308 Participants
2062 participants
n=2604 Participants
Region of Enrollment
Australia
80 participants
n=1296 Participants
68 participants
n=1308 Participants
148 participants
n=2604 Participants
Region of Enrollment
Germany
164 participants
n=1296 Participants
171 participants
n=1308 Participants
335 participants
n=2604 Participants
Region of Enrollment
Singapore
3 participants
n=1296 Participants
2 participants
n=1308 Participants
5 participants
n=2604 Participants
Prior Coronary Intervention
390 Participants
n=1294 Participants • The number of participants analyzed includes subjects who were available at that time of analysis
435 Participants
n=1307 Participants • The number of participants analyzed includes subjects who were available at that time of analysis
825 Participants
n=2601 Participants • The number of participants analyzed includes subjects who were available at that time of analysis

PRIMARY outcome

Timeframe: 30 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Target lesion failure (TLF) composite of Cardiac Death, Myocardial Infarction attributable to Target Vessel (TV-MI), or Ischemia-Driven Target Lesion Revascularization (ID-TLR))

Outcome measures

Outcome measures
Measure
XIENCE
n=1303 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1288 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Target Lesion Failure (TLF)
48 Participants
64 Participants

SECONDARY outcome

Timeframe: 1 year

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

One-sided p-value by using Farrington-Manning non-inferiority test will be used with non-inferiority margin of 4.8%, to be compared with a one-sided significance level of 0.025.

Outcome measures

Outcome measures
Measure
XIENCE
n=1272 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1254 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
TLF at 1-year, Non-inferiority Against the Control
82 Participants
98 Participants

SECONDARY outcome

Timeframe: 1 year

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

* Angina is defined as any angina or angina equivalent symptoms determined by the physician and/or research coordinator after interview of the patient, and as adjudicated by a clinical events committee (CEC). * This analysis will exclude angina or angina equivalent symptoms that occurred following the index procedure through hospital discharge or 7 days, whichever occurs first.

Outcome measures

Outcome measures
Measure
XIENCE
n=1265 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1248 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Angina at 1-year, Non-inferiority Against the Control
494 Participants
459 Participants

SECONDARY outcome

Timeframe: In-hospital (≤ 7days)

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Successful delivery and deployment of the study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system with attainment of final in-scaffold/stent residual stenosis of less than 30% by quantitative coronary angiography (QCA) (by visual estimation if QCA unavailable). When bailout scaffold/stent is used, the success or failure of the bailout scaffold/stent delivery and deployment is not one of the criteria for device success.

Outcome measures

Outcome measures
Measure
XIENCE
n=1450 Target lesions
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1424 Target lesions
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Percentage of Target Lesion With Acute Success- Device Success (Lesion Level Analysis)
99.0 Percentage of target lesions
94.6 Percentage of target lesions

SECONDARY outcome

Timeframe: In-hospital (≤ 7days)

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Achievement of final in-scaffold/stent residual stenosis of less than 30% by QCA (by visual estimation if QCA unavailable) with successful delivery and deployment of at least one study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system for all target lesions without the occurrence of cardiac death, target vessel MI or repeat TLR during the hospital stay (maximum of 7 days).

Outcome measures

Outcome measures
Measure
XIENCE
n=1303 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1282 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Acute Success- Procedural Success (Subject Level Analysis)
1246 Participants
1194 Participants

SECONDARY outcome

Timeframe: In-hospital (≤ 7 days post index procedure)

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.

Outcome measures

Outcome measures
Measure
XIENCE
n=1304 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1291 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Death (Cardiac, Vascular, Non-cardiovascular)
0 Participants
1 Participants

SECONDARY outcome

Timeframe: 30 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.

Outcome measures

Outcome measures
Measure
XIENCE
n=1303 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1288 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Death (Cardiac, Vascular, Non-cardiovascular)
1 Participants
1 Participants

SECONDARY outcome

Timeframe: 90 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.

Outcome measures

Outcome measures
Measure
XIENCE
n=1300 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1286 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Death (Cardiac, Vascular, Non-cardiovascular)
5 Participants
5 Participants

SECONDARY outcome

Timeframe: 180 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.

Outcome measures

Outcome measures
Measure
XIENCE
n=1291 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1282 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Death (Cardiac, Vascular, Non-cardiovascular)
8 Participants
7 Participants

SECONDARY outcome

Timeframe: 270 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.

Outcome measures

Outcome measures
Measure
XIENCE
n=1279 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1264 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Death (Cardiac, Vascular, Non-cardiovascular)
11 Participants
10 Participants

SECONDARY outcome

Timeframe: 1 year

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.

Outcome measures

Outcome measures
Measure
XIENCE
n=1273 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1255 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Death (Cardiac, Vascular, Non-cardiovascular)
15 Participants
16 Participants

SECONDARY outcome

Timeframe: 2 years

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.

Outcome measures

Outcome measures
Measure
XIENCE
n=1255 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1236 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Death (Cardiac, Vascular, Non-cardiovascular)
22 Participants
22 Participants

SECONDARY outcome

Timeframe: 3 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.

Outcome measures

Outcome measures
Measure
XIENCE
n=1241 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1219 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Death (Cardiac, Vascular, Non-cardiovascular)
32 Participants
39 Participants

SECONDARY outcome

Timeframe: 4 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.

Outcome measures

Outcome measures
Measure
XIENCE
n=1220 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1206 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Death (Cardiac, Vascular, Non-cardiovascular)
49 Participants
54 Participants

SECONDARY outcome

Timeframe: 5 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. For the All-Cause Mortality data, the denominator excludes participants who are lost-to-follow-up or withdrawn (by subject or physician) through a given timepoint without any DMR event (all death, MI and revascularization, respectively). If these participants were included in the denominator in each arm, that would equate to assuming that these participants are alive, potentially underestimating the death rate by inflating the denominator.

Outcome measures

Outcome measures
Measure
XIENCE
n=1200 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1189 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Death (Cardiac, Vascular, Non-cardiovascular)
72 Participants
77 Participants

SECONDARY outcome

Timeframe: In-hospital (≤ 7 days post index procedure)

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

* Attributable to target vessel (TV-MI) * Not attributable to target vessel (NTV-MI)

Outcome measures

Outcome measures
Measure
XIENCE
n=1304 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1291 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Myocardial Infarction (MI)
43 Participants
50 Participants

SECONDARY outcome

Timeframe: 30 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

* Attributable to target vessel (TV-MI) * Not attributable to target vessel (NTV-MI)

Outcome measures

Outcome measures
Measure
XIENCE
n=1303 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1288 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Myocardial Infarction (MI)
47 Participants
58 Participants

SECONDARY outcome

Timeframe: 90 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

* Attributable to target vessel (TV-MI) * Not attributable to target vessel (NTV-MI)

Outcome measures

Outcome measures
Measure
XIENCE
n=1300 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1286 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Myocardial Infarction (MI)
50 Participants
66 Participants

SECONDARY outcome

Timeframe: 180 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

* Attributable to target vessel (TV-MI) * Not attributable to target vessel (NTV-MI)

Outcome measures

Outcome measures
Measure
XIENCE
n=1291 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1282 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Myocardial Infarction (MI)
56 Participants
70 Participants

SECONDARY outcome

Timeframe: 270 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

* Attributable to target vessel (TV-MI) * Not attributable to target vessel (NTV-MI)

Outcome measures

Outcome measures
Measure
XIENCE
n=1279 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1264 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Myocardial Infarction (MI)
62 Participants
75 Participants

SECONDARY outcome

Timeframe: 1 year

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

* Attributable to target vessel (TV-MI) * Not attributable to target vessel (NTV-MI)

Outcome measures

Outcome measures
Measure
XIENCE
n=1273 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1255 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Myocardial Infarction (MI)
65 Participants
80 Participants

SECONDARY outcome

Timeframe: 2 years

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

* Attributable to target vessel (TV-MI) * Not attributable to target vessel (NTV-MI)

Outcome measures

Outcome measures
Measure
XIENCE
n=1255 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1236 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Myocardial Infarction (MI)
86 Participants
104 Participants

SECONDARY outcome

Timeframe: 3 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

* Attributable to target vessel (TV-MI) * Not attributable to target vessel (NTV-MI)

Outcome measures

Outcome measures
Measure
XIENCE
n=1241 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1219 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Myocardial Infarction (MI)
104 Participants
126 Participants

SECONDARY outcome

Timeframe: 4 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

* Attributable to target vessel (TV-MI) * Not attributable to target vessel (NTV-MI)

Outcome measures

Outcome measures
Measure
XIENCE
n=1220 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1206 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Myocardial Infarction (MI)
119 Participants
145 Participants

SECONDARY outcome

Timeframe: 5 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

* Attributable to target vessel (TV-MI) * Not attributable to target vessel (NTV-MI)

Outcome measures

Outcome measures
Measure
XIENCE
n=1200 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1189 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Myocardial Infarction (MI)
134 Participants
154 Participants

SECONDARY outcome

Timeframe: In-hospital (≤ 7 days post index procedure)

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame

Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)

Outcome measures

Outcome measures
Measure
XIENCE
n=1304 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1291 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Target Vessel Myocardial Infarction (TV-MI)
43 Participants
50 Participants

SECONDARY outcome

Timeframe: 30 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame

Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)

Outcome measures

Outcome measures
Measure
XIENCE
n=1303 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1288 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Target Vessel Myocardial Infarction (TV-MI)
47 Participants
57 Participants

SECONDARY outcome

Timeframe: 90 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)

Outcome measures

Outcome measures
Measure
XIENCE
n=1300 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1286 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Target Vessel Myocardial Infarction (TV-MI)
48 Participants
63 Participants

SECONDARY outcome

Timeframe: 180 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)

Outcome measures

Outcome measures
Measure
XIENCE
n=1291 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1282 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Target Vessel Myocardial Infarction (TV-MI)
53 Participants
67 Participants

SECONDARY outcome

Timeframe: 270 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)

Outcome measures

Outcome measures
Measure
XIENCE
n=1279 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1264 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Target Vessel Myocardial Infarction (TV-MI)
56 Participants
71 Participants

SECONDARY outcome

Timeframe: 1 year

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)

Outcome measures

Outcome measures
Measure
XIENCE
n=1273 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1255 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Target Vessel Myocardial Infarction (TV-MI)
58 Participants
75 Participants

SECONDARY outcome

Timeframe: 2 year

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)

Outcome measures

Outcome measures
Measure
XIENCE
n=1255 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1236 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Target Vessel Myocardial Infarction (TV-MI)
72 Participants
94 Participants

SECONDARY outcome

Timeframe: 3 years

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)

Outcome measures

Outcome measures
Measure
XIENCE
n=1241 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1219 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Target Vessel Myocardial Infarction (TV-MI)
86 Participants
112 Participants

SECONDARY outcome

Timeframe: 4 years

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)

Outcome measures

Outcome measures
Measure
XIENCE
n=1220 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1206 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Target Vessel Myocardial Infarction (TV-MI)
94 Participants
126 Participants

SECONDARY outcome

Timeframe: 5 years

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)

Outcome measures

Outcome measures
Measure
XIENCE
n=1200 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1189 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Target Vessel Myocardial Infarction (TV-MI)
106 Participants
134 Participants

SECONDARY outcome

Timeframe: In-hospital (≤ 7 days post index procedure)

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.

Outcome measures

Outcome measures
Measure
XIENCE
n=1304 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1291 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Target Lesion Revascularization (TLR)
1 Participants
8 Participants

SECONDARY outcome

Timeframe: 30 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.

Outcome measures

Outcome measures
Measure
XIENCE
n=1303 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1288 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Target Lesion Revascularization (TLR)
3 Participants
14 Participants

SECONDARY outcome

Timeframe: 90 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.

Outcome measures

Outcome measures
Measure
XIENCE
n=1300 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1286 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants withTarget Lesion Revascularization (TLR)
4 Participants
16 Participants

SECONDARY outcome

Timeframe: 180 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.

Outcome measures

Outcome measures
Measure
XIENCE
n=1291 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1282 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Target Lesion Revascularization (TLR)
11 Participants
23 Participants

SECONDARY outcome

Timeframe: 270 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.

Outcome measures

Outcome measures
Measure
XIENCE
n=1279 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1264 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Target Lesion Revascularization (TLR)
15 Participants
33 Participants

SECONDARY outcome

Timeframe: 1 year

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.

Outcome measures

Outcome measures
Measure
XIENCE
n=1273 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1255 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Target Lesion Revascularization (TLR)
24 Participants
38 Participants

SECONDARY outcome

Timeframe: 2 years

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.

Outcome measures

Outcome measures
Measure
XIENCE
n=1255 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1236 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Target Lesion Revascularization (TLR)
38 Participants
70 Participants

SECONDARY outcome

Timeframe: 3 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.

Outcome measures

Outcome measures
Measure
XIENCE
n=1241 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1219 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Target Lesion Revascularization (TLR)
50 Participants
90 Participants

SECONDARY outcome

Timeframe: 4 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.

Outcome measures

Outcome measures
Measure
XIENCE
n=1220 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1206 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Target Lesion Revascularization (TLR)
65 Participants
107 Participants

SECONDARY outcome

Timeframe: 5 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.

Outcome measures

Outcome measures
Measure
XIENCE
n=1200 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1189 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Target Lesion Revascularization (TLR)
82 Participants
114 Participants

SECONDARY outcome

Timeframe: In-hospital (≤ 7 days post index procedure)

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography

Outcome measures

Outcome measures
Measure
XIENCE
n=1304 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1291 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Ischemia Driven TLR (ID-TLR)
1 Participants
8 Participants

SECONDARY outcome

Timeframe: 30 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography

Outcome measures

Outcome measures
Measure
XIENCE
n=1303 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1288 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Ischemia Driven TLR (ID-TLR)
3 Participants
13 Participants

SECONDARY outcome

Timeframe: 90 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography

Outcome measures

Outcome measures
Measure
XIENCE
n=1300 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1286 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Ischemia Driven TLR (ID-TLR)
4 Participants
15 Participants

SECONDARY outcome

Timeframe: 180 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography

Outcome measures

Outcome measures
Measure
XIENCE
n=1291 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1282 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Ischemia Driven TLR (ID-TLR)
11 Participants
22 Participants

SECONDARY outcome

Timeframe: 270 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography

Outcome measures

Outcome measures
Measure
XIENCE
n=1279 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1264 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Ischemia Driven TLR (ID-TLR)
15 Participants
32 Participants

SECONDARY outcome

Timeframe: 1 year

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography

Outcome measures

Outcome measures
Measure
XIENCE
n=1273 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1255 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Ischemia Driven TLR (ID-TLR)
24 Participants
37 Participants

SECONDARY outcome

Timeframe: 2 years

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography

Outcome measures

Outcome measures
Measure
XIENCE
n=1255 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1236 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Ischemia Driven TLR (ID-TLR)
38 Participants
67 Participants

SECONDARY outcome

Timeframe: 3 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography

Outcome measures

Outcome measures
Measure
XIENCE
n=1241 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1219 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Ischemia Driven TLR (ID-TLR)
50 Participants
87 Participants

SECONDARY outcome

Timeframe: 4 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography

Outcome measures

Outcome measures
Measure
XIENCE
n=1220 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1206 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Ischemia Driven TLR (ID-TLR)
65 Participants
104 Participants

SECONDARY outcome

Timeframe: 5 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography

Outcome measures

Outcome measures
Measure
XIENCE
n=1200 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1189 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Ischemia Driven TLR (ID-TLR)
82 Participants
111 Participants

SECONDARY outcome

Timeframe: In-hospital (≤ 7 days post index procedure)

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. * TVR includes both Ischemic driven TVR and Non-ischemic driven TVR. * TVR includes all TVR, excluding TLR

Outcome measures

Outcome measures
Measure
XIENCE
n=1304 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1291 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Target Vessel Revascularization (TVR)
0 Participants
3 Participants

SECONDARY outcome

Timeframe: 30 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. * TVR includes both Ischemic driven TVR and Non-ischemic driven TVR. * TVR includes all TVR, excluding TLR

Outcome measures

Outcome measures
Measure
XIENCE
n=1303 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1288 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Target Vessel Revascularization (TVR)
1 Participants
5 Participants

SECONDARY outcome

Timeframe: 90 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. * TVR includes both Ischemic driven TVR and Non-ischemic driven TVR. * TVR includes all TVR, excluding TLR

Outcome measures

Outcome measures
Measure
XIENCE
n=1300 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1286 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Target Vessel Revascularization (TVR)
6 Participants
10 Participants

SECONDARY outcome

Timeframe: 180 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. classified as: Ischemic driven TVR and Non-ischemic driven TVR. -TVR includes all TVR, excluding TLR

Outcome measures

Outcome measures
Measure
XIENCE
n=1291 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1282 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Target Vessel Revascularization (TVR)
14 Participants
14 Participants

SECONDARY outcome

Timeframe: 270 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. * TVR includes both Ischemic driven TVR and Non-ischemic driven TVR. * TVR includes all TVR, excluding TLR

Outcome measures

Outcome measures
Measure
XIENCE
n=1279 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1264 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Target Vessel Revascularization (TVR)
16 Participants
19 Participants

SECONDARY outcome

Timeframe: 1 year

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. * TVR includes both Ischemic driven TVR and Non-ischemic driven TVR. * TVR includes all TVR, excluding TLR

Outcome measures

Outcome measures
Measure
XIENCE
n=1273 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1255 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Target Vessel Revascularization (TVR)
20 Participants
22 Participants

SECONDARY outcome

Timeframe: 2 years

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. * TVR includes both Ischemic driven TVR and Non-ischemic driven TVR. * TVR includes all TVR, excluding TLR

Outcome measures

Outcome measures
Measure
XIENCE
n=1255 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1236 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Target Vessel Revascularization (TVR)
39 Participants
44 Participants

SECONDARY outcome

Timeframe: 3 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. * TVR includes both Ischemic driven TVR and Non-ischemic driven TVR. * TVR includes all TVR, excluding TLR

Outcome measures

Outcome measures
Measure
XIENCE
n=1241 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1219 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Target Vessel Revascularization (TVR)
49 Participants
67 Participants

SECONDARY outcome

Timeframe: 4 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. * TVR includes both Ischemic driven TVR and Non-ischemic driven TVR. * TVR includes all TVR, excluding TLR

Outcome measures

Outcome measures
Measure
XIENCE
n=1220 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1206 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Target Vessel Revascularization (TVR)
66 Participants
82 Participants

SECONDARY outcome

Timeframe: 5 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. * TVR includes both Ischemic driven TVR and Non-ischemic driven TVR. * TVR includes all TVR, excluding TLR

Outcome measures

Outcome measures
Measure
XIENCE
n=1200 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1189 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Target Vessel Revascularization (TVR)
81 Participants
91 Participants

SECONDARY outcome

Timeframe: In-hospital (≤ 7 days post index procedure)

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. * TVR includes both Ischemic driven TVR and Non-ischemic driven TVR. * TVR includes all TVR, excluding TLR

Outcome measures

Outcome measures
Measure
XIENCE
n=1304 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1291 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With ID-TVR Excluding TLR
0 Participants
3 Participants

SECONDARY outcome

Timeframe: 30 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. * TVR includes both Ischemic driven TVR and Non-ischemic driven TVR. * TVR includes all TVR, excluding TLR

Outcome measures

Outcome measures
Measure
XIENCE
n=1303 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1288 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With ID-TVR Excluding TLR
1 Participants
5 Participants

SECONDARY outcome

Timeframe: 90 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. * TVR includes both Ischemic driven TVR and Non-ischemic driven TVR. * TVR includes all TVR, excluding TLR

Outcome measures

Outcome measures
Measure
XIENCE
n=1300 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1286 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With ID-TVR Excluding TLR
6 Participants
10 Participants

SECONDARY outcome

Timeframe: 180 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. * TVR includes both Ischemic driven TVR and Non-ischemic driven TVR. * TVR includes all TVR, excluding TLR

Outcome measures

Outcome measures
Measure
XIENCE
n=1291 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1282 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With ID-TVR Excluding TLR
14 Participants
14 Participants

SECONDARY outcome

Timeframe: 270 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. * TVR includes both Ischemic driven TVR and Non-ischemic driven TVR. * TVR includes all TVR, excluding TLR

Outcome measures

Outcome measures
Measure
XIENCE
n=1279 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1264 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With ID-TVR Excluding TLR
16 Participants
19 Participants

SECONDARY outcome

Timeframe: 1 year

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. * TVR includes both Ischemic driven TVR and Non-ischemic driven TVR. * TVR includes all TVR, excluding TLR

Outcome measures

Outcome measures
Measure
XIENCE
n=1273 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1255 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With ID-TVR Excluding TLR
20 Participants
22 Participants

SECONDARY outcome

Timeframe: 2 years

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. * TVR includes both Ischemic driven TVR and Non-ischemic driven TVR. * TVR includes all TVR, excluding TLR

Outcome measures

Outcome measures
Measure
XIENCE
n=1255 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1236 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With ID-TVR Excluding TLR
38 Participants
42 Participants

SECONDARY outcome

Timeframe: 3 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. * TVR includes both Ischemic driven TVR and Non-ischemic driven TVR. * TVR includes all TVR, excluding TLR

Outcome measures

Outcome measures
Measure
XIENCE
n=1241 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1219 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With ID-TVR Excluding TLR
48 Participants
65 Participants

SECONDARY outcome

Timeframe: 4 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. * TVR includes both Ischemic driven TVR and Non-ischemic driven TVR. * TVR includes all TVR, excluding TLR

Outcome measures

Outcome measures
Measure
XIENCE
n=1220 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1206 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With ID-TVR Excluding TLR
65 Participants
80 Participants

SECONDARY outcome

Timeframe: 5 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. * TVR includes both Ischemic driven TVR and Non-ischemic driven TVR. * TVR includes all TVR, excluding TLR

Outcome measures

Outcome measures
Measure
XIENCE
n=1200 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1189 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With ID-TVR Excluding TLR
80 Participants
89 Participants

SECONDARY outcome

Timeframe: In-hospital (≤ 7 days post index procedure)

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Revascularization includes TLR, TVR excluding TLR, and non TVR.

Outcome measures

Outcome measures
Measure
XIENCE
n=1304 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1291 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With All Coronary Revascularization
4 Participants
10 Participants

SECONDARY outcome

Timeframe: 30 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Revascularization includes TLR, TVR excluding TLR, and non TVR.

Outcome measures

Outcome measures
Measure
XIENCE
n=1303 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1288 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With All Coronary Revascularization
8 Participants
19 Participants

SECONDARY outcome

Timeframe: 90 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Revascularization includes TLR, TVR excluding TLR, and non TVR.

Outcome measures

Outcome measures
Measure
XIENCE
n=1300 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1286 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With All Coronary Revascularization
15 Participants
28 Participants

SECONDARY outcome

Timeframe: 180 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Revascularization includes TLR, TVR excluding TLR, and non TVR.

Outcome measures

Outcome measures
Measure
XIENCE
n=1291 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1282 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With All Coronary Revascularization
30 Participants
41 Participants

SECONDARY outcome

Timeframe: 270 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Revascularization includes TLR, TVR excluding TLR, and non TVR.

Outcome measures

Outcome measures
Measure
XIENCE
n=1279 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1264 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With All Coronary Revascularization
39 Participants
54 Participants

SECONDARY outcome

Timeframe: 1 year

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Revascularization includes TLR, TVR excluding TLR, and non TVR.

Outcome measures

Outcome measures
Measure
XIENCE
n=1273 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1255 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With All Coronary Revascularization
51 Participants
64 Participants

SECONDARY outcome

Timeframe: 2 years

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Revascularization includes TLR, TVR excluding TLR, and non TVR.

Outcome measures

Outcome measures
Measure
XIENCE
n=1255 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1236 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With All Coronary Revascularization
89 Participants
117 Participants

SECONDARY outcome

Timeframe: 3 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

Revascularization includes TLR, TVR excluding TLR, and non TVR.

Outcome measures

Outcome measures
Measure
XIENCE
n=1241 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1219 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With All Coronary Revascularization
113 Participants
157 Participants

SECONDARY outcome

Timeframe: 4 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

Revascularization includes TLR, TVR excluding TLR, and non TVR.

Outcome measures

Outcome measures
Measure
XIENCE
n=1220 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1206 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With All Coronary Revascularization
141 Participants
185 Participants

SECONDARY outcome

Timeframe: 5 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

Revascularization includes TLR, TVR excluding TLR, and non TVR.

Outcome measures

Outcome measures
Measure
XIENCE
n=1200 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1189 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With All Coronary Revascularization
167 Participants
198 Participants

SECONDARY outcome

Timeframe: In-hospital (≤ 7 days post index procedure)

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

All deaths includes * Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. * Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. * Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Those MIs which are not Q-wave MI

Outcome measures

Outcome measures
Measure
XIENCE
n=1304 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1291 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced All Death/All MI
43 Participants
51 Participants

SECONDARY outcome

Timeframe: 30 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

All deaths includes * Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. * Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. * Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Those MIs which are not Q-wave MI

Outcome measures

Outcome measures
Measure
XIENCE
n=1303 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1288 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced All Death/All MI
48 Participants
59 Participants

SECONDARY outcome

Timeframe: 90 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

All deaths includes * Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. * Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. * Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Those MIs which are not Q-wave MI

Outcome measures

Outcome measures
Measure
XIENCE
n=1300 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1286 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced All Death/All MI
55 Participants
69 Participants

SECONDARY outcome

Timeframe: 180 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

All deaths includes * Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. * Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. * Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Those MIs which are not Q-wave MI

Outcome measures

Outcome measures
Measure
XIENCE
n=1291 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1282 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced All Death/All MI
64 Participants
74 Participants

SECONDARY outcome

Timeframe: 270 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

All deaths includes * Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. * Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. * Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Those MIs which are not Q-wave MI

Outcome measures

Outcome measures
Measure
XIENCE
n=1279 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1264 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced All Death/All MI
72 Participants
80 Participants

SECONDARY outcome

Timeframe: 1 year

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

All deaths includes * Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. * Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. * Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Those MIs which are not Q-wave MI

Outcome measures

Outcome measures
Measure
XIENCE
n=1273 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1255 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced All Death/All MI
79 Participants
89 Participants

SECONDARY outcome

Timeframe: 2 years

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

All deaths includes * Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. * Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. * Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Those MIs which are not Q-wave MI

Outcome measures

Outcome measures
Measure
XIENCE
n=1255 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1236 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced All Death/All MI
106 Participants
116 Participants

SECONDARY outcome

Timeframe: 3 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

All deaths includes * Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. * Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. * Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Those MIs which are not Q-wave MI

Outcome measures

Outcome measures
Measure
XIENCE
n=1241 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1219 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced All Death/All MI
132 Participants
150 Participants

SECONDARY outcome

Timeframe: 4 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

All deaths includes * Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. * Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. * Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Those MIs which are not Q-wave MI

Outcome measures

Outcome measures
Measure
XIENCE
n=1220 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1206 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced All Death/All MI
159 Participants
181 Participants

SECONDARY outcome

Timeframe: 5 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

All deaths includes * Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. * Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. * Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Those MIs which are not Q-wave MI

Outcome measures

Outcome measures
Measure
XIENCE
n=1200 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1189 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced All Death/All MI
188 Participants
209 Participants

SECONDARY outcome

Timeframe: In-hospital (≤ 7 days post index procedure)

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.

Outcome measures

Outcome measures
Measure
XIENCE
n=1304 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1291 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Cardiac Death/All MI
43 Participants
51 Participants

SECONDARY outcome

Timeframe: 30 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.

Outcome measures

Outcome measures
Measure
XIENCE
n=1303 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1288 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Cardiac Death/All MI
47 Participants
59 Participants

SECONDARY outcome

Timeframe: 90 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.

Outcome measures

Outcome measures
Measure
XIENCE
n=1300 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1286 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Cardiac Death/All MI
53 Participants
67 Participants

SECONDARY outcome

Timeframe: 180 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.

Outcome measures

Outcome measures
Measure
XIENCE
n=1291 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1282 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Cardiac Death/All MI
61 Participants
71 Participants

SECONDARY outcome

Timeframe: 270 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.

Outcome measures

Outcome measures
Measure
XIENCE
n=1279 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1264 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Cardiac Death/All MI
68 Participants
77 Participants

SECONDARY outcome

Timeframe: 1 year

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.

Outcome measures

Outcome measures
Measure
XIENCE
n=1273 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1255 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Cardiac Death/All MI
73 Participants
83 Participants

SECONDARY outcome

Timeframe: 2 years

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.

Outcome measures

Outcome measures
Measure
XIENCE
n=1255 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1236 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Cardiac Death/All MI
96 Participants
107 Participants

SECONDARY outcome

Timeframe: 3 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.

Outcome measures

Outcome measures
Measure
XIENCE
n=1241 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1219 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Cardiac Death/All MI
118 Participants
133 Participants

SECONDARY outcome

Timeframe: 4 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.

Outcome measures

Outcome measures
Measure
XIENCE
n=1220 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1206 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Cardiac Death/All MI
137 Participants
157 Participants

SECONDARY outcome

Timeframe: 5 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.

Outcome measures

Outcome measures
Measure
XIENCE
n=1200 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1189 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Cardiac Death/All MI
155 Participants
171 Participants

SECONDARY outcome

Timeframe: In-hospital (≤ 7 days post index procedure)

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).

Outcome measures

Outcome measures
Measure
XIENCE
n=1304 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1291 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)
44 Participants
57 Participants

SECONDARY outcome

Timeframe: 30 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).

Outcome measures

Outcome measures
Measure
XIENCE
n=1303 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1288 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)
48 Participants
64 Participants

SECONDARY outcome

Timeframe: 90 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).

Outcome measures

Outcome measures
Measure
XIENCE
n=1300 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1286 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)
53 Participants
71 Participants

SECONDARY outcome

Timeframe: 180 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).

Outcome measures

Outcome measures
Measure
XIENCE
n=1291 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1282 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)
64 Participants
77 Participants

SECONDARY outcome

Timeframe: 270 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).

Outcome measures

Outcome measures
Measure
XIENCE
n=1279 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1264 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)
71 Participants
90 Participants

SECONDARY outcome

Timeframe: 1 year

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).

Outcome measures

Outcome measures
Measure
XIENCE
n=1273 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1255 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)
83 Participants
98 Participants

SECONDARY outcome

Timeframe: 2 years

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).

Outcome measures

Outcome measures
Measure
XIENCE
n=1255 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1236 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)
107 Participants
138 Participants

SECONDARY outcome

Timeframe: 3 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).

Outcome measures

Outcome measures
Measure
XIENCE
n=1241 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1219 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)
134 Participants
171 Participants

SECONDARY outcome

Timeframe: 4 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).

Outcome measures

Outcome measures
Measure
XIENCE
n=1220 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1206 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)
153 Participants
200 Participants

SECONDARY outcome

Timeframe: 5 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).

Outcome measures

Outcome measures
Measure
XIENCE
n=1200 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1189 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)
180 Participants
216 Participants

SECONDARY outcome

Timeframe: In-hospital (≤ 7 days post index procedure)

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).

Outcome measures

Outcome measures
Measure
XIENCE
n=1304 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1291 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Events-MACE)
44 Participants
57 Participants

SECONDARY outcome

Timeframe: 30 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).

Outcome measures

Outcome measures
Measure
XIENCE
n=1303 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1288 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced With Cardiac Death/All MI/ID-TLR (MACE)
48 Participants
65 Participants

SECONDARY outcome

Timeframe: 90 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).

Outcome measures

Outcome measures
Measure
XIENCE
n=1300 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1286 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)
55 Participants
74 Participants

SECONDARY outcome

Timeframe: 180 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).

Outcome measures

Outcome measures
Measure
XIENCE
n=1291 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1282 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)
67 Participants
80 Participants

SECONDARY outcome

Timeframe: 270 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).

Outcome measures

Outcome measures
Measure
XIENCE
n=1279 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1264 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)
77 Participants
93 Participants

SECONDARY outcome

Timeframe: 1 year

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).

Outcome measures

Outcome measures
Measure
XIENCE
n=1273 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1255 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)
89 Participants
102 Participants

SECONDARY outcome

Timeframe: 2 years

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).

Outcome measures

Outcome measures
Measure
XIENCE
n=1255 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1236 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)
121 Participants
146 Participants

SECONDARY outcome

Timeframe: 3 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).

Outcome measures

Outcome measures
Measure
XIENCE
n=1241 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1219 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)
152 Participants
183 Participants

SECONDARY outcome

Timeframe: 4 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).

Outcome measures

Outcome measures
Measure
XIENCE
n=1220 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1206 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)
178 Participants
217 Participants

SECONDARY outcome

Timeframe: 5 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).

Outcome measures

Outcome measures
Measure
XIENCE
n=1200 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1189 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)
207 Participants
233 Participants

SECONDARY outcome

Timeframe: In-hospital (≤ 7 days post index procedure)

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).

Outcome measures

Outcome measures
Measure
XIENCE
n=1304 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1291 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (Target Vessel Failure, TVF)
44 Participants
57 Participants

SECONDARY outcome

Timeframe: 30 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).

Outcome measures

Outcome measures
Measure
XIENCE
n=1303 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1288 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)
48 Participants
66 Participants

SECONDARY outcome

Timeframe: 90 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).

Outcome measures

Outcome measures
Measure
XIENCE
n=1300 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1286 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)
59 Participants
77 Participants

SECONDARY outcome

Timeframe: 180 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).

Outcome measures

Outcome measures
Measure
XIENCE
n=1291 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1282 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)
75 Participants
86 Participants

SECONDARY outcome

Timeframe: 270 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).

Outcome measures

Outcome measures
Measure
XIENCE
n=1279 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1264 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)
86 Participants
101 Participants

SECONDARY outcome

Timeframe: 1 year

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).

Outcome measures

Outcome measures
Measure
XIENCE
n=1273 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1255 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)
101 Participants
111 Participants

SECONDARY outcome

Timeframe: 2 years

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).

Outcome measures

Outcome measures
Measure
XIENCE
n=1255 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1236 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)
139 Participants
163 Participants

SECONDARY outcome

Timeframe: 3 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).

Outcome measures

Outcome measures
Measure
XIENCE
n=1241 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1219 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)
171 Participants
211 Participants

SECONDARY outcome

Timeframe: 4 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).

Outcome measures

Outcome measures
Measure
XIENCE
n=1220 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1206 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)
203 Participants
246 Participants

SECONDARY outcome

Timeframe: 5 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).

Outcome measures

Outcome measures
Measure
XIENCE
n=1200 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1189 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)
240 Participants
262 Participants

SECONDARY outcome

Timeframe: In-hospital (≤ 7 days post index procedure)

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.

Outcome measures

Outcome measures
Measure
XIENCE
n=1304 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1291 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Death/All MI/All Revascularization (DMR)
46 Participants
57 Participants

SECONDARY outcome

Timeframe: 30 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.

Outcome measures

Outcome measures
Measure
XIENCE
n=1303 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1288 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Death/All MI/All Revascularization (DMR)
53 Participants
67 Participants

SECONDARY outcome

Timeframe: 90 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.

Outcome measures

Outcome measures
Measure
XIENCE
n=1300 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1286 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Death/All MI/All Revascularization (DMR)
65 Participants
81 Participants

SECONDARY outcome

Timeframe: 180 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.

Outcome measures

Outcome measures
Measure
XIENCE
n=1291 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1282 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Death/All MI/All Revascularization (DMR)
82 Participants
94 Participants

SECONDARY outcome

Timeframe: 270 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.

Outcome measures

Outcome measures
Measure
XIENCE
n=1279 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1264 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Death/All MI/All Revascularization (DMR)
97 Participants
110 Participants

SECONDARY outcome

Timeframe: 1 year

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.

Outcome measures

Outcome measures
Measure
XIENCE
n=1273 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1255 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Death/All MI/All Revascularization (DMR)
114 Participants
125 Participants

SECONDARY outcome

Timeframe: 2 years

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.

Outcome measures

Outcome measures
Measure
XIENCE
n=1255 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1236 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Death/All MI/All Revascularization (DMR)
161 Participants
185 Participants

SECONDARY outcome

Timeframe: 3 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.

Outcome measures

Outcome measures
Measure
XIENCE
n=1241 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1219 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Death/All MI/All Revascularization (DMR)
198 Participants
241 Participants

SECONDARY outcome

Timeframe: 4 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.

Outcome measures

Outcome measures
Measure
XIENCE
n=1220 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1206 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Death/All MI/All Revascularization (DMR)
239 Participants
281 Participants

SECONDARY outcome

Timeframe: 5 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.

Outcome measures

Outcome measures
Measure
XIENCE
n=1200 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1189 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants Experienced Death/All MI/All Revascularization (DMR)
284 Participants
310 Participants

SECONDARY outcome

Timeframe: 0 - 24 hours post stent implantation

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (\>24 hours to 30 days post stent implantation), late (\>30 days to 1 year post stent implantation).

Outcome measures

Outcome measures
Measure
XIENCE
n=1305 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1291 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Acute Scaffold/Stent Thrombosis (Per Academic Research Consortium (ARC) Definition)
Definite
0 Participants
3 Participants
Number of Participants With Acute Scaffold/Stent Thrombosis (Per Academic Research Consortium (ARC) Definition)
Definite/Probable
0 Participants
4 Participants
Number of Participants With Acute Scaffold/Stent Thrombosis (Per Academic Research Consortium (ARC) Definition)
Probable
0 Participants
1 Participants

SECONDARY outcome

Timeframe: >24 hours - 30 days post stent implantation

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (\>24 hours to 30 days post stent implantation), late (\>30 days to 1 year post stent implantation).

Outcome measures

Outcome measures
Measure
XIENCE
n=1301 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1287 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Subacute Scaffold/Stent Thrombosis (Per ARC Definition)
Definite
2 Participants
4 Participants
Number of Participants With Subacute Scaffold/Stent Thrombosis (Per ARC Definition)
Definite/Probable
2 Participants
4 Participants
Number of Participants With Subacute Scaffold/Stent Thrombosis (Per ARC Definition)
Probable
0 Participants
0 Participants

SECONDARY outcome

Timeframe: 30 days - 1 year post stent implantation

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (\>24 hours to 30 days post stent implantation), late (\>30 days to 1 year post stent implantation).

Outcome measures

Outcome measures
Measure
XIENCE
n=1259 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1239 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Late Scaffold/Stent Thrombosis (Per ARC Definition)
Definite
2 Participants
1 Participants
Number of Participants With Late Scaffold/Stent Thrombosis (Per ARC Definition)
Definite/Probable
2 Participants
1 Participants
Number of Participants With Late Scaffold/Stent Thrombosis (Per ARC Definition)
Probable
0 Participants
0 Participants

SECONDARY outcome

Timeframe: 0 to 730 Days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained

Outcome measures

Outcome measures
Measure
XIENCE
n=1232 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1214 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Cumulative Scaffold/Stent Thrombosis (Per ARC Definition)
Definite
6 Participants
11 Participants
Number of Participants With Cumulative Scaffold/Stent Thrombosis (Per ARC Definition)
Definite/Probable
6 Participants
12 Participants
Number of Participants With Cumulative Scaffold/Stent Thrombosis (Per ARC Definition)
Probable
0 Participants
1 Participants

SECONDARY outcome

Timeframe: 30 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

* Coronary artery disease (CAD) related * Cardiovascular, non-CAD related * Non-cardiovascular related

Outcome measures

Outcome measures
Measure
XIENCE
n=1302 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1288 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Rehospitalization
59 Participants
66 Participants

SECONDARY outcome

Timeframe: 90 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

* CAD related * Cardiovascular, non-CAD related * Non-cardiovascular related

Outcome measures

Outcome measures
Measure
XIENCE
n=1298 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1285 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Rehospitalization
122 Participants
111 Participants

SECONDARY outcome

Timeframe: 180 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

* CAD related * Cardiovascular, non-CAD related * Non-cardiovascular related

Outcome measures

Outcome measures
Measure
XIENCE
n=1291 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1282 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Rehospitalization
178 Participants
178 Participants

SECONDARY outcome

Timeframe: 270 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

* CAD related * Cardiovascular, non-CAD related * Non-cardiovascular related

Outcome measures

Outcome measures
Measure
XIENCE
n=1278 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1265 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Rehospitalization
237 Participants
227 Participants

SECONDARY outcome

Timeframe: 1 year

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

* CAD related * Cardiovascular, non-CAD related * Non-cardiovascular related

Outcome measures

Outcome measures
Measure
XIENCE
n=1271 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1254 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Rehospitalization
289 Participants
277 Participants

SECONDARY outcome

Timeframe: 2 years

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

* CAD related * Cardiovascular, non-CAD related * Non-cardiovascular related

Outcome measures

Outcome measures
Measure
XIENCE
n=1254 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1238 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Rehospitalization
446 Participants
443 Participants

SECONDARY outcome

Timeframe: 3 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

* CAD related * Cardiovascular, non-CAD related * Non-cardiovascular related

Outcome measures

Outcome measures
Measure
XIENCE
n=1242 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1226 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Rehospitalization
525 Participants
544 Participants

SECONDARY outcome

Timeframe: 4 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

* CAD related * Cardiovascular, non-CAD related * Non-cardiovascular related

Outcome measures

Outcome measures
Measure
XIENCE
n=1226 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1215 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Rehospitalization
578 Participants
612 Participants

SECONDARY outcome

Timeframe: 5 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

* CAD related * Cardiovascular, non-CAD related * Non-cardiovascular related

Outcome measures

Outcome measures
Measure
XIENCE
n=1210 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1205 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Rehospitalization
621 Participants
654 Participants

SECONDARY outcome

Timeframe: In-hospital (≤ 7 days post index procedure)

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Outcome measures

Outcome measures
Measure
XIENCE
n=1304 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1290 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Repeat Coronary Arteriography
7 Participants
4 Participants

SECONDARY outcome

Timeframe: 30 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Outcome measures

Outcome measures
Measure
XIENCE
n=1301 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1288 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Repeat Coronary Arteriography
21 Participants
18 Participants

SECONDARY outcome

Timeframe: 90 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Outcome measures

Outcome measures
Measure
XIENCE
n=1295 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1282 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Repeat Coronary Arteriography
40 Participants
33 Participants

SECONDARY outcome

Timeframe: 180 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Outcome measures

Outcome measures
Measure
XIENCE
n=1284 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1278 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Repeat Coronary Arteriography
64 Participants
57 Participants

SECONDARY outcome

Timeframe: 270 days

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Outcome measures

Outcome measures
Measure
XIENCE
n=1270 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1259 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Repeat Coronary Arteriography
87 Participants
71 Participants

SECONDARY outcome

Timeframe: 1 year

Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Outcome measures

Outcome measures
Measure
XIENCE
n=1260 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1242 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Repeat Coronary Arteriography
103 Participants
84 Participants

SECONDARY outcome

Timeframe: 2 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

Outcome measures

Outcome measures
Measure
XIENCE
n=1237 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1218 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Repeat Coronary Arteriography
161 Participants
140 Participants

SECONDARY outcome

Timeframe: 3 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

Outcome measures

Outcome measures
Measure
XIENCE
n=1212 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1186 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Repeat Coronary Arteriography
188 Participants
186 Participants

SECONDARY outcome

Timeframe: 4 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

Outcome measures

Outcome measures
Measure
XIENCE
n=1178 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1157 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Repeat Coronary Arteriography
220 Participants
209 Participants

SECONDARY outcome

Timeframe: 5 years

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

Outcome measures

Outcome measures
Measure
XIENCE
n=1144 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1125 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Repeat Coronary Arteriography
237 Participants
225 Participants

SECONDARY outcome

Timeframe: 1 year

Population: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

The analysis will be based on 4610 subjects (2000 primary analysis subjects of ABSORB III and 2610 subjects of ABSORB IV)

Outcome measures

Outcome measures
Measure
XIENCE
n=1273 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
Absorb BVS
n=1255 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Number of Participants With Target Lesion Failure (TLF)
83 Participants
98 Participants

Adverse Events

Absorb BVS

Serious events: 827 serious events
Other events: 1012 other events
Deaths: 77 deaths

XIENCE

Serious events: 774 serious events
Other events: 1034 other events
Deaths: 72 deaths

Serious adverse events

Serious adverse events
Measure
Absorb BVS
n=1296 participants at risk
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS)
XIENCE
n=1308 participants at risk
Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
Renal and urinary disorders
RENAL FAILURE ACUTE
2.1%
27/1296 • 5 years
1.7%
22/1308 • 5 years
Eye disorders
CATARACT
0.31%
4/1296 • 5 years
0.38%
5/1308 • 5 years
Investigations
CORONAVIRUS TEST POSITIVE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Investigations
EJECTION FRACTION DECREASED
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Blood and lymphatic system disorders
ANAEMIA
0.85%
11/1296 • 5 years
1.3%
17/1308 • 5 years
Blood and lymphatic system disorders
FEBRILE NEUTROPENIA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Blood and lymphatic system disorders
HAEMORRHAGIC ANAEMIA
0.23%
3/1296 • 5 years
0.15%
2/1308 • 5 years
Blood and lymphatic system disorders
IRON DEFICIENCY ANAEMIA
0.31%
4/1296 • 5 years
0.31%
4/1308 • 5 years
Blood and lymphatic system disorders
NORMOCHROMIC NORMOCYTIC ANAEMIA
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Blood and lymphatic system disorders
PANCYTOPENIA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Blood and lymphatic system disorders
THROMBOCYTOPENIA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
ACUTE CORONARY SYNDROME
0.77%
10/1296 • 5 years
0.54%
7/1308 • 5 years
Cardiac disorders
ACUTE LEFT VENTRICULAR FAILURE
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
ACUTE MYOCARDIAL INFARCTION
1.8%
23/1296 • 5 years
2.0%
26/1308 • 5 years
Cardiac disorders
ANGINA PECTORIS
10.4%
135/1296 • 5 years
8.6%
113/1308 • 5 years
Cardiac disorders
ANGINA UNSTABLE
4.1%
53/1296 • 5 years
4.4%
57/1308 • 5 years
Cardiac disorders
AORTIC VALVE INCOMPETENCE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
AORTIC VALVE STENOSIS
0.15%
2/1296 • 5 years
0.23%
3/1308 • 5 years
Cardiac disorders
ARRHYTHMIA
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Cardiac disorders
ARTERIOSCLEROSIS CORONARY ARTERY
0.31%
4/1296 • 5 years
0.15%
2/1308 • 5 years
Cardiac disorders
ARTERIOSPASM CORONARY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
ATRIAL FIBRILLATION
3.5%
45/1296 • 5 years
2.4%
32/1308 • 5 years
Cardiac disorders
ATRIAL FLUTTER
0.23%
3/1296 • 5 years
0.15%
2/1308 • 5 years
Cardiac disorders
ATRIAL TACHYCARDIA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
ATRIAL THROMBOSIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
ATRIOVENTRICULAR BLOCK
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
ATRIOVENTRICULAR BLOCK COMPLETE
0.15%
2/1296 • 5 years
0.23%
3/1308 • 5 years
Cardiac disorders
ATRIOVENTRICULAR BLOCK SECOND DEGREE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
BRADYCARDIA
0.31%
4/1296 • 5 years
0.31%
4/1308 • 5 years
Cardiac disorders
BUNDLE BRANCH BLOCK LEFT
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
CARDIAC ARREST
0.77%
10/1296 • 5 years
0.31%
4/1308 • 5 years
Cardiac disorders
CARDIAC FAILURE
1.0%
13/1296 • 5 years
0.23%
3/1308 • 5 years
Cardiac disorders
CARDIAC FAILURE ACUTE
0.31%
4/1296 • 5 years
0.38%
5/1308 • 5 years
Cardiac disorders
CARDIAC FAILURE CHRONIC
0.31%
4/1296 • 5 years
0.15%
2/1308 • 5 years
Cardiac disorders
CARDIAC FAILURE CONGESTIVE
1.9%
24/1296 • 5 years
1.8%
23/1308 • 5 years
Cardiac disorders
CARDIAC PERFORATION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
CARDIAC TAMPONADE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
CARDIAC VALVE DISEASE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
CARDIO-RESPIRATORY ARREST
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Cardiac disorders
CARDIOGENIC SHOCK
0.39%
5/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
CARDIOMYOPATHY
0.23%
3/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
CARDIOPULMONARY FAILURE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
CHRONOTROPIC INCOMPETENCE
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
CONGESTIVE CARDIOMYOPATHY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
COR PULMONALE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
CORONARY ARTERY DISEASE
3.5%
45/1296 • 5 years
3.0%
39/1308 • 5 years
Cardiac disorders
CORONARY ARTERY DISSECTION
3.2%
41/1296 • 5 years
1.3%
17/1308 • 5 years
Cardiac disorders
CORONARY ARTERY EMBOLISM
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
CORONARY ARTERY OCCLUSION
0.23%
3/1296 • 5 years
0.31%
4/1308 • 5 years
Cardiac disorders
CORONARY ARTERY PERFORATION
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
CORONARY ARTERY STENOSIS
1.1%
14/1296 • 5 years
1.1%
15/1308 • 5 years
Cardiac disorders
HYPERTENSIVE HEART DISEASE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
HYPERTROPHIC CARDIOMYOPATHY
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
IN-STENT CORONARY ARTERY RESTENOSIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
INTRACARDIAC THROMBUS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
INTRAPERICARDIAL THROMBOSIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
ISCHAEMIC CARDIOMYOPATHY
0.23%
3/1296 • 5 years
0.38%
5/1308 • 5 years
Cardiac disorders
MITRAL VALVE INCOMPETENCE
0.23%
3/1296 • 5 years
0.15%
2/1308 • 5 years
Cardiac disorders
MITRAL VALVE PROLAPSE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
MITRAL VALVE STENOSIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
MYOCARDIAL INFARCTION
5.2%
67/1296 • 5 years
4.1%
54/1308 • 5 years
Cardiac disorders
MYOCARDIAL ISCHAEMIA
0.39%
5/1296 • 5 years
0.38%
5/1308 • 5 years
Cardiac disorders
MYOCARDITIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
MYOPERICARDITIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
PALPITATIONS
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Cardiac disorders
PERICARDIAL EFFUSION
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
PERICARDIAL HAEMORRHAGE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
PERICARDITIS
0.15%
2/1296 • 5 years
0.15%
2/1308 • 5 years
Cardiac disorders
PRINZMETAL ANGINA
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
PULSELESS ELECTRICAL ACTIVITY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
SICK SINUS SYNDROME
0.39%
5/1296 • 5 years
0.31%
4/1308 • 5 years
Cardiac disorders
STRESS CARDIOMYOPATHY
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
SUPRAVENTRICULAR TACHYCARDIA
0.23%
3/1296 • 5 years
0.38%
5/1308 • 5 years
Cardiac disorders
TACHYCARDIA
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
TRICUSPID VALVE INCOMPETENCE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
VENTRICULAR EXTRASYSTOLES
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
VENTRICULAR FIBRILLATION
0.39%
5/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
VENTRICULAR TACHYCARDIA
0.23%
3/1296 • 5 years
0.46%
6/1308 • 5 years
Congenital, familial and genetic disorders
ARTERIOVENOUS MALFORMATION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Congenital, familial and genetic disorders
ATRIAL SEPTAL DEFECT
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Congenital, familial and genetic disorders
CORNEAL DYSTROPHY
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Congenital, familial and genetic disorders
GASTROINTESTINAL ARTERIOVENOUS MALFORMATION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Congenital, familial and genetic disorders
HYDROCELE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Congenital, familial and genetic disorders
PERONEAL MUSCULAR ATROPHY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Congenital, familial and genetic disorders
PHIMOSIS
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Congenital, familial and genetic disorders
URACHAL ABNORMALITY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Ear and labyrinth disorders
VERTIGO
0.15%
2/1296 • 5 years
0.31%
4/1308 • 5 years
Ear and labyrinth disorders
VERTIGO POSITIONAL
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Endocrine disorders
ADRENAL INSUFFICIENCY
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Endocrine disorders
CARCINOID SYNDROME
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Endocrine disorders
GOITRE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Endocrine disorders
HYPERPARATHYROIDISM
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Endocrine disorders
HYPOTHYROIDIC GOITRE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Endocrine disorders
THYROID MASS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Eye disorders
AMAUROSIS FUGAX
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Eye disorders
DIPLOPIA
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Eye disorders
GLAUCOMA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Eye disorders
MACULAR FIBROSIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Eye disorders
RETINAL ARTERY EMBOLISM
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Eye disorders
RETINAL DETACHMENT
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Eye disorders
RETINAL DISORDER
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Eye disorders
TOLOSA-HUNT SYNDROME
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Eye disorders
VITREOUS HAEMORRHAGE
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Gastrointestinal disorders
ABDOMINAL HERNIA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
ABDOMINAL MASS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
ABDOMINAL PAIN
0.54%
7/1296 • 5 years
0.38%
5/1308 • 5 years
Gastrointestinal disorders
ABDOMINAL PAIN LOWER
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
ABDOMINAL PAIN UPPER
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
ANAL HAEMORRHAGE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
ASCITES
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
BARRETT'S OESOPHAGUS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
CHRONIC GASTROINTESTINAL BLEEDING
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
COLITIS
0.54%
7/1296 • 5 years
0.31%
4/1308 • 5 years
Gastrointestinal disorders
COLITIS ISCHAEMIC
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Gastrointestinal disorders
COLITIS ULCERATIVE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
COLONIC POLYP
0.31%
4/1296 • 5 years
0.31%
4/1308 • 5 years
Gastrointestinal disorders
CONSTIPATION
0.08%
1/1296 • 5 years
0.23%
3/1308 • 5 years
Gastrointestinal disorders
CROHN'S DISEASE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
DENTAL CARIES
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
DIARRHOEA
0.08%
1/1296 • 5 years
0.31%
4/1308 • 5 years
Gastrointestinal disorders
DIVERTICULAR PERFORATION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
DIVERTICULITIS INTESTINAL HAEMORRHAGIC
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Gastrointestinal disorders
DIVERTICULUM
0.15%
2/1296 • 5 years
0.15%
2/1308 • 5 years
Gastrointestinal disorders
DIVERTICULUM INTESTINAL
0.00%
0/1296 • 5 years
0.31%
4/1308 • 5 years
Gastrointestinal disorders
DIVERTICULUM INTESTINAL HAEMORRHAGIC
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
DUODENAL PERFORATION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
DUODENAL ULCER
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
DUODENAL ULCER PERFORATION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
DYSPEPSIA
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
DYSPHAGIA
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
ENTERITIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
ENTEROCOLITIS HAEMORRHAGIC
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
ENTEROVESICAL FISTULA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
FAECALOMA
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
GASTRIC DISORDER
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
GASTRIC ULCER
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
GASTRIC ULCER HAEMORRHAGE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
GASTRITIS
0.23%
3/1296 • 5 years
0.38%
5/1308 • 5 years
Gastrointestinal disorders
GASTRITIS EROSIVE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
GASTRITIS HAEMORRHAGIC
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
GASTROINTESTINAL HAEMORRHAGE
1.1%
14/1296 • 5 years
0.99%
13/1308 • 5 years
Gastrointestinal disorders
GASTROINTESTINAL MUCOSAL EXFOLIATION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
GASTROINTESTINAL ULCER HAEMORRHAGE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
GASTROOESOPHAGEAL REFLUX DISEASE
0.23%
3/1296 • 5 years
0.31%
4/1308 • 5 years
Infections and infestations
TOOTH ABSCESS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
GINGIVAL BLEEDING
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
HAEMATEMESIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
HAEMATOCHEZIA
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
HAEMORRHOIDAL HAEMORRHAGE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
HAEMORRHOIDS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
HIATUS HERNIA
0.23%
3/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
ILEUS
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Gastrointestinal disorders
IMPAIRED GASTRIC EMPTYING
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
INGUINAL HERNIA
1.0%
13/1296 • 5 years
0.31%
4/1308 • 5 years
Gastrointestinal disorders
INGUINAL HERNIA, OBSTRUCTIVE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
INTESTINAL HAEMORRHAGE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
INTESTINAL ISCHAEMIA
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
INTESTINAL MASS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
LARGE INTESTINE PERFORATION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
LOWER GASTROINTESTINAL HAEMORRHAGE
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
MALLORY-WEISS SYNDROME
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
MELAENA
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
MESENTERIC HAEMORRHAGE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
NAUSEA
0.15%
2/1296 • 5 years
0.15%
2/1308 • 5 years
Gastrointestinal disorders
OBSTRUCTION GASTRIC
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
OESOPHAGEAL STENOSIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
OESOPHAGITIS
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Gastrointestinal disorders
PANCREATIC MASS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
PANCREATITIS
0.08%
1/1296 • 5 years
0.46%
6/1308 • 5 years
Gastrointestinal disorders
PANCREATITIS ACUTE
0.08%
1/1296 • 5 years
0.38%
5/1308 • 5 years
Gastrointestinal disorders
PANCREATITIS CHRONIC
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Gastrointestinal disorders
PROCTALGIA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
PROCTITIS ULCERATIVE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
RECTAL HAEMORRHAGE
0.08%
1/1296 • 5 years
0.46%
6/1308 • 5 years
Gastrointestinal disorders
RECTAL POLYP
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Gastrointestinal disorders
RETROPERITONEAL HAEMORRHAGE
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
SMALL INTESTINAL OBSTRUCTION
0.77%
10/1296 • 5 years
0.46%
6/1308 • 5 years
Gastrointestinal disorders
SPIGELIAN HERNIA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
STOMATITIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
UMBILICAL HERNIA
0.15%
2/1296 • 5 years
0.15%
2/1308 • 5 years
Gastrointestinal disorders
UPPER GASTROINTESTINAL HAEMORRHAGE
0.54%
7/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
VOLVULUS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
VOMITING
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
General disorders
ADVERSE DRUG REACTION
0.23%
3/1296 • 5 years
0.54%
7/1308 • 5 years
General disorders
ASTHENIA
0.23%
3/1296 • 5 years
0.31%
4/1308 • 5 years
General disorders
CARDIAC COMPLICATION ASSOCIATED WITH DEVICE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
General disorders
CARDIAC DEATH
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
General disorders
CATHETER SITE HAEMATOMA
0.31%
4/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
CATHETER SITE NECROSIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
CHEST DISCOMFORT
0.62%
8/1296 • 5 years
0.54%
7/1308 • 5 years
General disorders
CHEST PAIN
2.8%
36/1296 • 5 years
2.2%
29/1308 • 5 years
General disorders
CHILLS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
COMPLICATION OF DEVICE REMOVAL
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
General disorders
DEATH
0.54%
7/1296 • 5 years
0.84%
11/1308 • 5 years
General disorders
DEVICE BREAKAGE
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
DEVICE FAILURE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
DEVICE ISSUE
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
DEVICE MALFUNCTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
General disorders
DEVICE MATERIAL ISSUE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
DISEASE PROGRESSION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
EARLY SATIETY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
FACIAL PAIN
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
FATIGUE
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
General disorders
GAIT DISTURBANCE
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
GENERAL PHYSICAL HEALTH DETERIORATION
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
General disorders
HERNIA
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
General disorders
HYPERTHERMIA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
General disorders
IMPAIRED HEALING
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
General disorders
MALAISE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
MEDICAL DEVICE COMPLICATION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
MEDICAL DEVICE PAIN
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
General disorders
MEDICAL DEVICE SITE REACTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
General disorders
METAPLASIA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
MULTI-ORGAN FAILURE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
NON-CARDIAC CHEST PAIN
5.9%
76/1296 • 5 years
6.3%
83/1308 • 5 years
General disorders
OEDEMA PERIPHERAL
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
General disorders
PAIN
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
PYREXIA
0.46%
6/1296 • 5 years
0.00%
0/1308 • 5 years
General disorders
STENT-GRAFT ENDOLEAK
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
SUDDEN CARDIAC DEATH
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
SYSTEMIC INFLAMMATORY RESPONSE SYNDROME
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
General disorders
THROMBOSIS IN DEVICE
0.93%
12/1296 • 5 years
0.99%
13/1308 • 5 years
General disorders
ULCER
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Hepatobiliary disorders
ACUTE HEPATIC FAILURE
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Hepatobiliary disorders
BILE DUCT OBSTRUCTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Hepatobiliary disorders
BILE DUCT STONE
0.23%
3/1296 • 5 years
0.31%
4/1308 • 5 years
Hepatobiliary disorders
BILIARY COLIC
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Hepatobiliary disorders
BILIARY DYSKINESIA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Hepatobiliary disorders
CHOLANGITIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Hepatobiliary disorders
CHOLANGITIS ACUTE
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Hepatobiliary disorders
CHOLECYSTITIS
0.23%
3/1296 • 5 years
0.23%
3/1308 • 5 years
Hepatobiliary disorders
CHOLECYSTITIS ACUTE
0.23%
3/1296 • 5 years
0.23%
3/1308 • 5 years
Hepatobiliary disorders
CHOLECYSTITIS CHRONIC
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Hepatobiliary disorders
CHOLELITHIASIS
0.69%
9/1296 • 5 years
0.31%
4/1308 • 5 years
Hepatobiliary disorders
CIRRHOSIS ALCOHOLIC
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Hepatobiliary disorders
GALLBLADDER DISORDER
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Hepatobiliary disorders
HEPATIC CIRRHOSIS
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Hepatobiliary disorders
HEPATIC FAILURE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Hepatobiliary disorders
HEPATIC STEATOSIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Hepatobiliary disorders
HEPATORENAL FAILURE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Hepatobiliary disorders
ISCHAEMIC HEPATITIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Hepatobiliary disorders
JAUNDICE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Hepatobiliary disorders
JAUNDICE CHOLESTATIC
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Hepatobiliary disorders
NON-ALCOHOLIC STEATOHEPATITIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Immune system disorders
ALLERGY TO ARTHROPOD STING
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Immune system disorders
AMYLOIDOSIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Immune system disorders
ANAPHYLACTIC REACTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Immune system disorders
DRUG HYPERSENSITIVITY
0.23%
3/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
ABDOMINAL ABSCESS
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Infections and infestations
ABDOMINAL SEPSIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
ABSCESS LIMB
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
ABSCESS NECK
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
ABSCESS OF SALIVARY GLAND
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
ABSCESS ORAL
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
APPENDICITIS
0.31%
4/1296 • 5 years
0.31%
4/1308 • 5 years
Infections and infestations
ARTERIOVENOUS GRAFT SITE INFECTION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
ARTHRITIS INFECTIVE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
BACTERAEMIA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
BACTERIAL SEPSIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
BRONCHIOLITIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
BRONCHITIS
0.46%
6/1296 • 5 years
0.23%
3/1308 • 5 years
Infections and infestations
BRONCHITIS VIRAL
0.00%
0/1296 • 5 years
0.23%
3/1308 • 5 years
Infections and infestations
BRONCHOPNEUMONIA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
BURSITIS INFECTIVE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
CELLULITIS
0.62%
8/1296 • 5 years
0.61%
8/1308 • 5 years
Infections and infestations
CELLULITIS OF MALE EXTERNAL GENITAL ORGAN
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
CHOLECYSTITIS INFECTIVE
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Infections and infestations
CLOSTRIDIAL INFECTION
0.08%
1/1296 • 5 years
0.23%
3/1308 • 5 years
Infections and infestations
CLOSTRIDIUM COLITIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
CLOSTRIDIUM DIFFICILE COLITIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
CORONA VIRUS INFECTION
0.54%
7/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
CYSTITIS
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
DEVICE RELATED INFECTION
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
DIABETIC FOOT INFECTION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
DIVERTICULITIS
0.69%
9/1296 • 5 years
0.69%
9/1308 • 5 years
Infections and infestations
EAR INFECTION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
EMPYEMA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
ENDOCARDITIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
ENTEROCOCCAL BACTERAEMIA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
ENTEROCOLITIS INFECTIOUS
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
ESCHERICHIA BACTERAEMIA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
ESCHERICHIA INFECTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
ESCHERICHIA SEPSIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
ESCHERICHIA URINARY TRACT INFECTION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
EXTRADURAL ABSCESS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
GANGRENE
0.23%
3/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
GASTRIC INFECTION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
GASTROENTERITIS
0.46%
6/1296 • 5 years
0.46%
6/1308 • 5 years
Infections and infestations
GASTROENTERITIS VIRAL
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
HEPATITIS C
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
HERPES ZOSTER
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
HERPES ZOSTER OTICUS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
IMPLANT SITE INFECTION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
INCISION SITE INFECTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
INFECTED DERMAL CYST
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
INFECTED SKIN ULCER
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
INFECTIOUS PLEURAL EFFUSION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
INFLUENZA
0.39%
5/1296 • 5 years
0.38%
5/1308 • 5 years
Infections and infestations
KLEBSIELLA BACTERAEMIA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
KLEBSIELLA SEPSIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
LABYRINTHITIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
LIVER ABSCESS
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
LOBAR PNEUMONIA
0.31%
4/1296 • 5 years
0.38%
5/1308 • 5 years
Infections and infestations
LOWER RESPIRATORY TRACT INFECTION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
LUNG INFECTION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
LUNG INFECTION PSEUDOMONAL
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
MUSCLE ABSCESS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
NECROTISING FASCIITIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
OSTEOMYELITIS
0.00%
0/1296 • 5 years
0.38%
5/1308 • 5 years
Infections and infestations
OSTEOMYELITIS CHRONIC
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
PERIUMBILICAL ABSCESS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
PHARYNGEAL ABSCESS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
PHARYNGITIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
PLEURAL INFECTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
PNEUMONIA
2.9%
37/1296 • 5 years
2.6%
34/1308 • 5 years
Infections and infestations
PNEUMONIA KLEBSIELLA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
PNEUMONIA STREPTOCOCCAL
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
PNEUMONIA VIRAL
0.08%
1/1296 • 5 years
0.31%
4/1308 • 5 years
Infections and infestations
POST PROCEDURAL CELLULITIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
POSTOPERATIVE ABSCESS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
POSTOPERATIVE WOUND INFECTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
PYELONEPHRITIS
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Infections and infestations
PYELONEPHRITIS ACUTE
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
RHINOVIRUS INFECTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
SCROTAL ABSCESS
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
SEPSIS
1.5%
19/1296 • 5 years
1.1%
14/1308 • 5 years
Infections and infestations
SEPSIS SYNDROME
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
SEPTIC ENCEPHALOPATHY
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
SEPTIC SHOCK
0.15%
2/1296 • 5 years
0.31%
4/1308 • 5 years
Infections and infestations
STAPHYLOCOCCAL BACTERAEMIA
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
STAPHYLOCOCCAL INFECTION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
STAPHYLOCOCCAL SEPSIS
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
SUBCUTANEOUS ABSCESS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
TESTICULAR ABSCESS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
TOOTH INFECTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
UPPER RESPIRATORY TRACT INFECTION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
URETHRITIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
URINARY TRACT INFECTION
0.77%
10/1296 • 5 years
1.1%
14/1308 • 5 years
Infections and infestations
UROSEPSIS
0.39%
5/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
VIRAL INFECTION
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
VIRAL LABYRINTHITIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
WEST NILE VIRAL INFECTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
WOUND INFECTION
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
WOUND INFECTION BACTERIAL
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
ACETABULUM FRACTURE
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
ADRENAL GLAND INJURY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
ALCOHOL POISONING
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
ANAEMIA POSTOPERATIVE
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
ANASTOMOTIC LEAK
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
ANASTOMOTIC ULCER HAEMORRHAGE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
ANKLE FRACTURE
0.15%
2/1296 • 5 years
0.61%
8/1308 • 5 years
Injury, poisoning and procedural complications
ARTERIAL INJURY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
ARTHROPOD STING
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
ASBESTOSIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
BACK INJURY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
CARDIAC PROCEDURE COMPLICATION
0.15%
2/1296 • 5 years
0.15%
2/1308 • 5 years
Injury, poisoning and procedural complications
CATHETER SITE HAEMATOMA
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
CERVICAL VERTEBRAL FRACTURE
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Injury, poisoning and procedural complications
COMMINUTED FRACTURE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
CONCUSSION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
CONFUSION POSTOPERATIVE
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
CONTUSION
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Injury, poisoning and procedural complications
CORONARY ARTERY REOCCLUSION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
CORONARY ARTERY RESTENOSIS
2.2%
28/1296 • 5 years
1.5%
20/1308 • 5 years
Injury, poisoning and procedural complications
CRANIOCEREBRAL INJURY
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
CYSTITIS RADIATION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
FACIAL BONES FRACTURE
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
FALL
0.46%
6/1296 • 5 years
0.31%
4/1308 • 5 years
Injury, poisoning and procedural complications
FEMORAL NECK FRACTURE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
FEMUR FRACTURE
0.23%
3/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
FIBULA FRACTURE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
FOOT FRACTURE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
FOREARM FRACTURE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
FRACTURE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
GASTROINTESTINAL STOMA COMPLICATION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
HAEMATURIA TRAUMATIC
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
HAND FRACTURE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
HEAT EXHAUSTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
HEAT STROKE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
HIP FRACTURE
0.15%
2/1296 • 5 years
0.15%
2/1308 • 5 years
Injury, poisoning and procedural complications
HUMERUS FRACTURE
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
IN-STENT ARTERIAL RESTENOSIS
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
IN-STENT CORONARY ARTERY RESTENOSIS
0.62%
8/1296 • 5 years
1.4%
18/1308 • 5 years
Injury, poisoning and procedural complications
INCISIONAL HERNIA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
INJURY
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
INTENTIONAL OVERDOSE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
JOINT DISLOCATION
0.00%
0/1296 • 5 years
0.23%
3/1308 • 5 years
Injury, poisoning and procedural complications
LACERATION
0.23%
3/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
LIGAMENT RUPTURE
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
LIMB INJURY
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
LUMBAR VERTEBRAL FRACTURE
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
MENISCUS LESION
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Injury, poisoning and procedural complications
MULTIPLE FRACTURES
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
MULTIPLE INJURIES
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
OVERDOSE
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
PATELLA FRACTURE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
PELVIC FRACTURE
0.00%
0/1296 • 5 years
0.23%
3/1308 • 5 years
Injury, poisoning and procedural complications
PELVIC ORGAN INJURY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
PERIPROSTHETIC FRACTURE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
PLAQUE SHIFT
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
POISONING
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
POISONING DELIBERATE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
POST LAMINECTOMY SYNDROME
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
POST PROCEDURAL BILE LEAK
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
POST PROCEDURAL COMPLICATION
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
POST PROCEDURAL HAEMORRHAGE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
POST PROCEDURAL MYOCARDIAL INFARCTION
0.85%
11/1296 • 5 years
0.46%
6/1308 • 5 years
Injury, poisoning and procedural complications
POST-TRAUMATIC PAIN
0.00%
0/1296 • 5 years
0.23%
3/1308 • 5 years
Injury, poisoning and procedural complications
POSTOPERATIVE ILEUS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
POSTOPERATIVE RESPIRATORY DISTRESS
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
PROCEDURAL HYPERTENSION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
PROCEDURAL PAIN
0.23%
3/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
PROCEDURAL VOMITING
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
RADIUS FRACTURE
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
RIB FRACTURE
0.23%
3/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
ROAD TRAFFIC ACCIDENT
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
SKULL FRACTURE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
SPINAL COLUMN INJURY
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
SPINAL COMPRESSION FRACTURE
0.31%
4/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
SPINAL FRACTURE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
STAB WOUND
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
STRESS ECHOCARDIOGRAM ABNORMAL
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
SUBDURAL HAEMATOMA
0.08%
1/1296 • 5 years
0.23%
3/1308 • 5 years
Injury, poisoning and procedural complications
SUBDURAL HAEMORRHAGE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
TENDON RUPTURE
0.15%
2/1296 • 5 years
0.23%
3/1308 • 5 years
Injury, poisoning and procedural complications
THERMAL BURN
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
THORACIC VERTEBRAL FRACTURE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
TRAUMATIC ARTHRITIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
TRAUMATIC HAEMATOMA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
TRAUMATIC HAEMORRHAGE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
TRAUMATIC INTRACRANIAL HAEMORRHAGE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
TRAUMATIC LUNG INJURY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
ULNA FRACTURE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
UPPER LIMB FRACTURE
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
URINARY RETENTION POSTOPERATIVE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
VASCULAR GRAFT COMPLICATION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
VASCULAR GRAFT OCCLUSION
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Injury, poisoning and procedural complications
VASCULAR PSEUDOANEURYSM
0.31%
4/1296 • 5 years
0.38%
5/1308 • 5 years
Injury, poisoning and procedural complications
WOUND DEHISCENCE
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
WRIST FRACTURE
0.00%
0/1296 • 5 years
0.23%
3/1308 • 5 years
Investigations
ARTERIOGRAM CORONARY
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Investigations
BLOOD CREATINE PHOSPHOKINASE INCREASED
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Investigations
BLOOD CREATINE PHOSPHOKINASE MB INCREASED
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Investigations
BLOOD GLUCOSE DECREASED
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Investigations
BLOOD GLUCOSE INCREASED
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Investigations
BLOOD PRESSURE INCREASED
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Investigations
CARDIAC ENZYMES INCREASED
0.31%
4/1296 • 5 years
0.31%
4/1308 • 5 years
Investigations
CARDIAC STRESS TEST ABNORMAL
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Investigations
ELECTROCARDIOGRAM ABNORMAL
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Investigations
GLYCOSYLATED HAEMOGLOBIN INCREASED
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Investigations
N-TERMINAL PROHORMONE BRAIN NATRIURETIC PEPTIDE INCREASED
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Investigations
TRANSAMINASES INCREASED
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Investigations
TROPONIN INCREASED
0.46%
6/1296 • 5 years
0.15%
2/1308 • 5 years
Metabolism and nutrition disorders
DEHYDRATION
0.46%
6/1296 • 5 years
0.31%
4/1308 • 5 years
Metabolism and nutrition disorders
DIABETES MELLITUS
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Metabolism and nutrition disorders
DIABETES MELLITUS INADEQUATE CONTROL
0.31%
4/1296 • 5 years
0.00%
0/1308 • 5 years
Metabolism and nutrition disorders
DIABETIC KETOACIDOSIS
0.15%
2/1296 • 5 years
0.38%
5/1308 • 5 years
Metabolism and nutrition disorders
FAILURE TO THRIVE
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Metabolism and nutrition disorders
FLUID OVERLOAD
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Metabolism and nutrition disorders
GOUT
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Metabolism and nutrition disorders
HYPERAMMONAEMIA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Metabolism and nutrition disorders
HYPERCALCAEMIA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Metabolism and nutrition disorders
HYPERGLYCAEMIA
0.23%
3/1296 • 5 years
0.08%
1/1308 • 5 years
Metabolism and nutrition disorders
HYPERKALAEMIA
0.23%
3/1296 • 5 years
0.00%
0/1308 • 5 years
Metabolism and nutrition disorders
HYPOGLYCAEMIA
0.15%
2/1296 • 5 years
0.31%
4/1308 • 5 years
Metabolism and nutrition disorders
HYPOKALAEMIA
0.00%
0/1296 • 5 years
0.23%
3/1308 • 5 years
Metabolism and nutrition disorders
HYPOMAGNESAEMIA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Metabolism and nutrition disorders
HYPONATRAEMIA
0.00%
0/1296 • 5 years
0.38%
5/1308 • 5 years
Metabolism and nutrition disorders
HYPOVOLAEMIA
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Metabolism and nutrition disorders
KETOACIDOSIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Metabolism and nutrition disorders
LACTIC ACIDOSIS
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Metabolism and nutrition disorders
MALNUTRITION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Metabolism and nutrition disorders
METABOLIC ACIDOSIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Metabolism and nutrition disorders
METABOLIC SYNDROME
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Metabolism and nutrition disorders
OBESITY
0.08%
1/1296 • 5 years
0.31%
4/1308 • 5 years
Metabolism and nutrition disorders
TYPE 2 DIABETES MELLITUS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Musculoskeletal and connective tissue disorders
ARTHRALGIA
0.54%
7/1296 • 5 years
0.46%
6/1308 • 5 years
Musculoskeletal and connective tissue disorders
ARTHRITIS
0.46%
6/1296 • 5 years
0.23%
3/1308 • 5 years
Musculoskeletal and connective tissue disorders
ARTHROPATHY
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Musculoskeletal and connective tissue disorders
BACK PAIN
0.77%
10/1296 • 5 years
0.69%
9/1308 • 5 years
Musculoskeletal and connective tissue disorders
BURSITIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Musculoskeletal and connective tissue disorders
CERVICAL SPINAL STENOSIS
0.15%
2/1296 • 5 years
0.31%
4/1308 • 5 years
Musculoskeletal and connective tissue disorders
CHONDROCALCINOSIS PYROPHOSPHATE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Musculoskeletal and connective tissue disorders
COSTOCHONDRITIS
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Musculoskeletal and connective tissue disorders
FACET JOINT SYNDROME
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Musculoskeletal and connective tissue disorders
FEMOROACETABULAR IMPINGEMENT
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Musculoskeletal and connective tissue disorders
FOOT DEFORMITY
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Musculoskeletal and connective tissue disorders
INTERVERTEBRAL DISC DEGENERATION
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Musculoskeletal and connective tissue disorders
INTERVERTEBRAL DISC PROTRUSION
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Musculoskeletal and connective tissue disorders
JOINT SWELLING
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Musculoskeletal and connective tissue disorders
LUMBAR SPINAL STENOSIS
0.31%
4/1296 • 5 years
0.31%
4/1308 • 5 years
Musculoskeletal and connective tissue disorders
MUSCLE NECROSIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Musculoskeletal and connective tissue disorders
MUSCLE SPASMS
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Musculoskeletal and connective tissue disorders
MUSCULAR WEAKNESS
0.15%
2/1296 • 5 years
0.15%
2/1308 • 5 years
Musculoskeletal and connective tissue disorders
MUSCULOSKELETAL CHEST PAIN
0.08%
1/1296 • 5 years
0.38%
5/1308 • 5 years
Musculoskeletal and connective tissue disorders
MUSCULOSKELETAL DISCOMFORT
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Musculoskeletal and connective tissue disorders
MUSCULOSKELETAL PAIN
0.31%
4/1296 • 5 years
0.61%
8/1308 • 5 years
Musculoskeletal and connective tissue disorders
MYALGIA
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Musculoskeletal and connective tissue disorders
MYOPATHY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Musculoskeletal and connective tissue disorders
NECK PAIN
0.23%
3/1296 • 5 years
0.08%
1/1308 • 5 years
Musculoskeletal and connective tissue disorders
OSTEOARTHRITIS
2.2%
29/1296 • 5 years
1.8%
24/1308 • 5 years
Musculoskeletal and connective tissue disorders
OSTEOCHONDROSIS
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Musculoskeletal and connective tissue disorders
OSTEONECROSIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Musculoskeletal and connective tissue disorders
OSTEOPOROSIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Musculoskeletal and connective tissue disorders
PAIN IN EXTREMITY
0.31%
4/1296 • 5 years
0.38%
5/1308 • 5 years
Musculoskeletal and connective tissue disorders
POLYMYALGIA RHEUMATICA
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Musculoskeletal and connective tissue disorders
PSEUDARTHROSIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Musculoskeletal and connective tissue disorders
RHABDOMYOLYSIS
0.23%
3/1296 • 5 years
0.00%
0/1308 • 5 years
Musculoskeletal and connective tissue disorders
RHEUMATOID ARTHRITIS
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Musculoskeletal and connective tissue disorders
ROTATOR CUFF SYNDROME
0.46%
6/1296 • 5 years
0.46%
6/1308 • 5 years
Musculoskeletal and connective tissue disorders
SPINAL COLUMN STENOSIS
0.23%
3/1296 • 5 years
0.23%
3/1308 • 5 years
Musculoskeletal and connective tissue disorders
SPINAL DISORDER
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Musculoskeletal and connective tissue disorders
SPINAL OSTEOARTHRITIS
0.15%
2/1296 • 5 years
0.38%
5/1308 • 5 years
Musculoskeletal and connective tissue disorders
TENDONITIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Musculoskeletal and connective tissue disorders
TENOSYNOVITIS STENOSANS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Musculoskeletal and connective tissue disorders
TRIGGER FINGER
0.00%
0/1296 • 5 years
0.23%
3/1308 • 5 years
Musculoskeletal and connective tissue disorders
VERTEBRAL FORAMINAL STENOSIS
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
ACUTE MYELOID LEUKAEMIA
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
ACUTE PROMYELOCYTIC LEUKAEMIA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
ADENOCARCINOMA
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
ADENOCARCINOMA PANCREAS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-CELL LYMPHOMA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-CELL LYMPHOMA STAGE I
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-CELL LYMPHOMA STAGE IV
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BASAL CELL CARCINOMA
0.23%
3/1296 • 5 years
0.46%
6/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BENIGN NEOPLASM OF BLADDER
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BENIGN SOFT TISSUE NEOPLASM
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BILE DUCT CANCER
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BLADDER CANCER
0.46%
6/1296 • 5 years
0.31%
4/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BLADDER NEOPLASM
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BOWEN'S DISEASE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BREAST CANCER
0.31%
4/1296 • 5 years
0.38%
5/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BREAST CANCER IN SITU
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BREAST CANCER STAGE II
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BRONCHIAL CARCINOMA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
CHRONIC LYMPHOCYTIC LEUKAEMIA
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
COLON ADENOMA
0.23%
3/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
COLON CANCER
0.46%
6/1296 • 5 years
0.38%
5/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
ENDOMETRIAL CANCER
0.15%
2/1296 • 5 years
0.15%
2/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
ENDOMETRIAL CANCER METASTATIC
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
GASTROINTESTINAL STROMAL TUMOUR
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
HEPATIC NEOPLASM
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
HEPATIC NEOPLASM MALIGNANT
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
HEPATIC NEOPLASM MALIGNANT RECURRENT
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
INTESTINAL ADENOCARCINOMA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LARYNGEAL CANCER
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LUNG ADENOCARCINOMA
0.15%
2/1296 • 5 years
0.15%
2/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LUNG ADENOCARCINOMA METASTATIC
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LUNG CANCER METASTATIC
0.23%
3/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LUNG CARCINOMA CELL TYPE UNSPECIFIED STAGE IV
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LUNG NEOPLASM
0.23%
3/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LUNG NEOPLASM MALIGNANT
0.46%
6/1296 • 5 years
0.31%
4/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LUNG SQUAMOUS CELL CARCINOMA STAGE UNSPECIFIED
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LYMPHOMA
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MALIGNANT GLIOMA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MALIGNANT MELANOMA
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MALIGNANT MELANOMA IN SITU
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MALIGNANT PLEURAL EFFUSION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MANTLE CELL LYMPHOMA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MELANOCYTIC NAEVUS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MENINGIOMA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
METASTASES TO CENTRAL NERVOUS SYSTEM
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
METASTASES TO LIVER
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
METASTATIC MALIGNANT MELANOMA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
METASTATIC NEOPLASM
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MUELLER'S MIXED TUMOUR
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MULTIPLE MYELOMA
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MYELODYSPLASTIC SYNDROME
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MYELOFIBROSIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
NEOPLASM MALIGNANT
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
NEOPLASM SKIN
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
NEUROENDOCRINE CARCINOMA METASTATIC
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
NON-HODGKIN'S LYMPHOMA
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
NON-SMALL CELL LUNG CANCER
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
OESOPHAGEAL CARCINOMA
0.08%
1/1296 • 5 years
0.23%
3/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
OROPHARYNGEAL CANCER STAGE UNSPECIFIED
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
OVARIAN CANCER METASTATIC
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
OVARIAN CANCER STAGE III
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
OVARIAN NEOPLASM
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PANCREATIC CARCINOMA
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PANCREATIC CARCINOMA METASTATIC
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PARATHYROID TUMOUR BENIGN
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PERITONEAL CARCINOMA METASTATIC
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PLASMACYTOMA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PLEURAL MESOTHELIOMA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PLEURAL MESOTHELIOMA MALIGNANT
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PROSTATE CANCER
0.62%
8/1296 • 5 years
0.46%
6/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PROSTATE CANCER METASTATIC
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
RECTAL ADENOMA
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
RECTAL CANCER
0.23%
3/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
RENAL CANCER
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
RENAL CELL CARCINOMA
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SALIVARY GLAND CANCER
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SALIVARY GLAND NEOPLASM
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SEBORRHOEIC KERATOSIS
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SKIN CANCER
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SMALL CELL LUNG CANCER STAGE UNSPECIFIED
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SQUAMOUS CELL CARCINOMA
0.15%
2/1296 • 5 years
0.15%
2/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SQUAMOUS CELL CARCINOMA OF SKIN
0.00%
0/1296 • 5 years
0.23%
3/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
THYROID CANCER
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
TRACHEAL CANCER
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
TRANSITIONAL CELL CARCINOMA
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
URETERIC CANCER RECURRENT
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
AMNESIA
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
APHASIA
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Nervous system disorders
BRAIN INJURY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
BRAIN MASS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
BRAIN STEM INFARCTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
CAROTID ARTERY OCCLUSION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
CAROTID ARTERY STENOSIS
0.85%
11/1296 • 5 years
0.61%
8/1308 • 5 years
Nervous system disorders
CARPAL TUNNEL SYNDROME
0.23%
3/1296 • 5 years
0.15%
2/1308 • 5 years
Nervous system disorders
CENTRAL NERVOUS SYSTEM LESION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
CEREBELLAR INFARCTION
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Nervous system disorders
CEREBRAL HAEMORRHAGE
0.15%
2/1296 • 5 years
0.23%
3/1308 • 5 years
Nervous system disorders
CEREBRAL INFARCTION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
CEREBROVASCULAR ACCIDENT
1.2%
15/1296 • 5 years
1.6%
21/1308 • 5 years
Nervous system disorders
CEREBROVASCULAR DISORDER
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
CERVICAL CORD COMPRESSION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
CERVICAL MYELOPATHY
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
CERVICOBRACHIAL SYNDROME
0.00%
0/1296 • 5 years
0.23%
3/1308 • 5 years
Nervous system disorders
CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
COMPLICATED MIGRAINE
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
CONVULSION
0.23%
3/1296 • 5 years
0.15%
2/1308 • 5 years
Nervous system disorders
CRANIAL NERVE DISORDER
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
CUBITAL TUNNEL SYNDROME
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
DEMENTIA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
DEMENTIA ALZHEIMER'S TYPE
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
DEPRESSED LEVEL OF CONSCIOUSNESS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
DIZZINESS
0.31%
4/1296 • 5 years
0.54%
7/1308 • 5 years
Nervous system disorders
DYSARTHRIA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
EMBOLIC CEREBRAL INFARCTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
ENCEPHALOPATHY
0.39%
5/1296 • 5 years
0.15%
2/1308 • 5 years
Nervous system disorders
EPILEPSY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
GRAND MAL CONVULSION
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
GUILLAIN-BARRE SYNDROME
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
HAEMORRHAGE INTRACRANIAL
0.08%
1/1296 • 5 years
0.23%
3/1308 • 5 years
Nervous system disorders
HAEMORRHAGIC STROKE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
HEADACHE
0.23%
3/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
HYPOAESTHESIA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
IIIRD NERVE PARALYSIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
INTRACRANIAL ANEURYSM
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
INTRAVENTRICULAR HAEMORRHAGE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
ISCHAEMIC STROKE
0.08%
1/1296 • 5 years
0.23%
3/1308 • 5 years
Nervous system disorders
LUMBAR RADICULOPATHY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
METABOLIC ENCEPHALOPATHY
0.46%
6/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
MIGRAINE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
MIGRAINE WITH AURA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
MONONEURITIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
MULTIPLE SCLEROSIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
NEURODEGENERATIVE DISORDER
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
PARKINSON'S DISEASE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
PARTIAL SEIZURES
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
PERIPHERAL SENSORY NEUROPATHY
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
PRESYNCOPE
0.39%
5/1296 • 5 years
0.38%
5/1308 • 5 years
Nervous system disorders
RADICULOPATHY
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
SCIATICA
0.23%
3/1296 • 5 years
0.23%
3/1308 • 5 years
Nervous system disorders
SENSORY LOSS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
SUBARACHNOID HAEMORRHAGE
0.00%
0/1296 • 5 years
0.31%
4/1308 • 5 years
Nervous system disorders
SYNCOPE
1.2%
15/1296 • 5 years
1.3%
17/1308 • 5 years
Nervous system disorders
TOXIC ENCEPHALOPATHY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
TRANSIENT ISCHAEMIC ATTACK
1.1%
14/1296 • 5 years
0.84%
11/1308 • 5 years
Nervous system disorders
TREMOR
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
TRIGEMINAL NEURALGIA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
TYPICAL AURA WITHOUT HEADACHE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
ULNAR TUNNEL SYNDROME
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
UNRESPONSIVE TO STIMULI
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
VERTEBRAL ARTERY STENOSIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
VIITH NERVE PARALYSIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Pregnancy, puerperium and perinatal conditions
ABORTION SPONTANEOUS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Psychiatric disorders
ALCOHOL WITHDRAWAL SYNDROME
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Psychiatric disorders
ANXIETY
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Psychiatric disorders
COMPLETED SUICIDE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Psychiatric disorders
CONFUSIONAL STATE
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Psychiatric disorders
CONVERSION DISORDER
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Psychiatric disorders
DELIRIUM
0.15%
2/1296 • 5 years
0.15%
2/1308 • 5 years
Psychiatric disorders
DEPRESSION
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Psychiatric disorders
DEPRESSION SUICIDAL
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Psychiatric disorders
IMPAIRED SELF-CARE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Psychiatric disorders
INTENTIONAL SELF-INJURY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Psychiatric disorders
MENTAL DISORDER DUE TO A GENERAL MEDICAL CONDITION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Psychiatric disorders
MENTAL STATUS CHANGES
0.39%
5/1296 • 5 years
0.38%
5/1308 • 5 years
Psychiatric disorders
POST-TRAUMATIC AMNESTIC DISORDER
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Psychiatric disorders
PSYCHOGENIC PAIN DISORDER
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Psychiatric disorders
SOMATOFORM DISORDER
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Psychiatric disorders
SUICIDAL IDEATION
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Psychiatric disorders
SUICIDE ATTEMPT
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Renal and urinary disorders
BLADDER NECK OBSTRUCTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Renal and urinary disorders
BLADDER OBSTRUCTION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Renal and urinary disorders
BLADDER PERFORATION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Renal and urinary disorders
CALCULUS BLADDER
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Renal and urinary disorders
CALCULUS URETERIC
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Renal and urinary disorders
CYSTITIS HAEMORRHAGIC
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Renal and urinary disorders
DYSURIA
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Renal and urinary disorders
HAEMATURIA
0.39%
5/1296 • 5 years
0.38%
5/1308 • 5 years
Renal and urinary disorders
HYDRONEPHROSIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Renal and urinary disorders
HYPERTONIC BLADDER
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Renal and urinary disorders
NEPHROLITHIASIS
0.54%
7/1296 • 5 years
0.54%
7/1308 • 5 years
Renal and urinary disorders
OBSTRUCTIVE UROPATHY
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Renal and urinary disorders
RENAL ARTERY STENOSIS
0.15%
2/1296 • 5 years
0.23%
3/1308 • 5 years
Renal and urinary disorders
RENAL FAILURE
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Renal and urinary disorders
RENAL FAILURE CHRONIC
0.08%
1/1296 • 5 years
0.31%
4/1308 • 5 years
Renal and urinary disorders
RENAL HAEMORRHAGE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Renal and urinary disorders
RENAL IMPAIRMENT
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Renal and urinary disorders
RENAL MASS
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Renal and urinary disorders
URETERIC STENOSIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Renal and urinary disorders
URINARY INCONTINENCE
0.08%
1/1296 • 5 years
0.23%
3/1308 • 5 years
Renal and urinary disorders
URINARY RETENTION
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Reproductive system and breast disorders
ACQUIRED HYDROCELE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Reproductive system and breast disorders
BENIGN PROSTATIC HYPERPLASIA
0.39%
5/1296 • 5 years
0.54%
7/1308 • 5 years
Reproductive system and breast disorders
ENDOMETRIAL HYPERPLASIA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Reproductive system and breast disorders
EPIDIDYMITIS
0.08%
1/1296 • 5 years
0.23%
3/1308 • 5 years
Reproductive system and breast disorders
ERECTILE DYSFUNCTION
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Reproductive system and breast disorders
GENITAL PAIN
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Reproductive system and breast disorders
GYNAECOMASTIA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Reproductive system and breast disorders
MENORRHAGIA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Reproductive system and breast disorders
PELVIC PROLAPSE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Reproductive system and breast disorders
PROSTATITIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Reproductive system and breast disorders
PROSTATOMEGALY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Reproductive system and breast disorders
UTERINE OBSTRUCTION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Reproductive system and breast disorders
UTERINE POLYP
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Reproductive system and breast disorders
VAGINAL HAEMORRHAGE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Reproductive system and breast disorders
VAGINAL PROLAPSE
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Reproductive system and breast disorders
VULVAR DYSPLASIA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
ACQUIRED DIAPHRAGMATIC EVENTRATION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
ACUTE INTERSTITIAL PNEUMONITIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
ACUTE PULMONARY OEDEMA
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
ACUTE RESPIRATORY DISTRESS SYNDROME
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
ACUTE RESPIRATORY FAILURE
1.2%
15/1296 • 5 years
1.4%
18/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
ASPIRATION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
ASTHMA
0.23%
3/1296 • 5 years
0.08%
1/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
ATELECTASIS
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
1.2%
16/1296 • 5 years
1.3%
17/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
CHRONIC RESPIRATORY FAILURE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
DIAPHRAGMATIC PARALYSIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
DYSPNOEA
1.6%
21/1296 • 5 years
1.8%
24/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
DYSPNOEA EXERTIONAL
0.69%
9/1296 • 5 years
0.76%
10/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
EMPHYSEMA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
EPISTAXIS
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
HAEMOPTYSIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
HAEMOTHORAX
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
HYPOXIA
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
INTERSTITIAL LUNG DISEASE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
LUNG INFILTRATION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
NASAL SEPTUM DEVIATION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
NASAL TURBINATE HYPERTROPHY
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
PHARYNGEAL MASS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
PLEURAL EFFUSION
0.31%
4/1296 • 5 years
0.15%
2/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
PLEURAL FIBROSIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
PLEURITIC PAIN
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
PNEUMONIA ASPIRATION
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
PNEUMONITIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
PNEUMOTHORAX
0.23%
3/1296 • 5 years
0.15%
2/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
PULMONARY EMBOLISM
0.62%
8/1296 • 5 years
0.38%
5/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
PULMONARY FIBROSIS
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
PULMONARY HYPERTENSION
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
PULMONARY MASS
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
PULMONARY OEDEMA
0.08%
1/1296 • 5 years
0.23%
3/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
PULMONARY TOXICITY
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
RESPIRATORY ARREST
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
RESPIRATORY DISTRESS
0.23%
3/1296 • 5 years
0.08%
1/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
RESPIRATORY FAILURE
0.93%
12/1296 • 5 years
0.38%
5/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
SLEEP APNOEA SYNDROME
0.08%
1/1296 • 5 years
0.23%
3/1308 • 5 years
Skin and subcutaneous tissue disorders
ANGIOEDEMA
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Skin and subcutaneous tissue disorders
DECUBITUS ULCER
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Skin and subcutaneous tissue disorders
DIGITAL ULCER
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Skin and subcutaneous tissue disorders
DRUG ERUPTION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Skin and subcutaneous tissue disorders
DRY GANGRENE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Skin and subcutaneous tissue disorders
LEUKOCYTOCLASTIC VASCULITIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Skin and subcutaneous tissue disorders
PRECANCEROUS SKIN LESION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Skin and subcutaneous tissue disorders
RASH
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Skin and subcutaneous tissue disorders
SCAR PAIN
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Skin and subcutaneous tissue disorders
SKIN ULCER
0.08%
1/1296 • 5 years
0.23%
3/1308 • 5 years
Surgical and medical procedures
AORTIC STENT INSERTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Surgical and medical procedures
CORONARY ARTERIAL STENT INSERTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Surgical and medical procedures
HERNIA REPAIR
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Surgical and medical procedures
HIP ARTHROPLASTY
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Surgical and medical procedures
HYSTERECTOMY
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Surgical and medical procedures
IMPLANTABLE DEFIBRILLATOR INSERTION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Surgical and medical procedures
KNEE ARTHROPLASTY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Surgical and medical procedures
NASAL OPERATION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Surgical and medical procedures
NECK SURGERY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Surgical and medical procedures
PERCUTANEOUS CORONARY INTERVENTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Surgical and medical procedures
ROTATOR CUFF REPAIR
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Surgical and medical procedures
SURGERY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Vascular disorders
ACCELERATED HYPERTENSION
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Vascular disorders
ANEURYSM
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Vascular disorders
AORTIC ANEURYSM
0.08%
1/1296 • 5 years
0.31%
4/1308 • 5 years
Vascular disorders
AORTIC DISSECTION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Vascular disorders
AORTIC STENOSIS
0.31%
4/1296 • 5 years
0.23%
3/1308 • 5 years
Vascular disorders
ARTERIAL DISORDER
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Vascular disorders
ARTERIAL HAEMORRHAGE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Vascular disorders
ARTERIAL OCCLUSIVE DISEASE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Vascular disorders
ARTERIAL THROMBOSIS LIMB
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Vascular disorders
ARTERIOSCLEROSIS
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Vascular disorders
DEEP VEIN THROMBOSIS
0.31%
4/1296 • 5 years
0.31%
4/1308 • 5 years
Vascular disorders
EMBOLISM ARTERIAL
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Vascular disorders
FEMORAL ARTERIAL STENOSIS
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Vascular disorders
FEMORAL ARTERY ANEURYSM
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Vascular disorders
FEMORAL ARTERY DISSECTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Vascular disorders
FEMORAL ARTERY OCCLUSION
0.15%
2/1296 • 5 years
0.15%
2/1308 • 5 years
Vascular disorders
HAEMATOMA
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Vascular disorders
HYPERTENSION
0.46%
6/1296 • 5 years
0.31%
4/1308 • 5 years
Vascular disorders
HYPERTENSIVE CRISIS
0.39%
5/1296 • 5 years
0.76%
10/1308 • 5 years
Vascular disorders
HYPERTENSIVE EMERGENCY
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Vascular disorders
HYPOTENSION
0.39%
5/1296 • 5 years
0.38%
5/1308 • 5 years
Vascular disorders
HYPOVOLAEMIC SHOCK
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Vascular disorders
ILIAC ARTERY STENOSIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Vascular disorders
INTERMITTENT CLAUDICATION
0.62%
8/1296 • 5 years
0.23%
3/1308 • 5 years
Vascular disorders
LERICHE SYNDROME
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Vascular disorders
MALIGNANT HYPERTENSION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Vascular disorders
ORTHOSTATIC HYPOTENSION
0.31%
4/1296 • 5 years
0.23%
3/1308 • 5 years
Vascular disorders
PELVIC VENOUS THROMBOSIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Vascular disorders
PERIPHERAL ARTERIAL OCCLUSIVE DISEASE
0.54%
7/1296 • 5 years
1.1%
15/1308 • 5 years
Vascular disorders
PERIPHERAL ISCHAEMIA
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Vascular disorders
PERIPHERAL VASCULAR DISORDER
0.39%
5/1296 • 5 years
0.38%
5/1308 • 5 years
Vascular disorders
SHOCK
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Vascular disorders
THROMBOPHLEBITIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Vascular disorders
THROMBOSIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Vascular disorders
VARICOSE VEIN
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Vascular disorders
VASCULAR STENOSIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Vascular disorders
VENOUS RECANALISATION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Vascular disorders
VENOUS THROMBOSIS LIMB
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years

Other adverse events

Other adverse events
Measure
Absorb BVS
n=1296 participants at risk
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS)
XIENCE
n=1308 participants at risk
Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
Nervous system disorders
HYPOAESTHESIA
2.1%
27/1296 • 5 years
1.4%
18/1308 • 5 years
Nervous system disorders
IIIRD NERVE PARALYSIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Congenital, familial and genetic disorders
PHIMOSIS
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Congenital, familial and genetic disorders
URACHAL ABNORMALITY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
INTESTINAL HAEMORRHAGE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
INTESTINAL ISCHAEMIA
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Ear and labyrinth disorders
CERUMEN IMPACTION
0.08%
1/1296 • 5 years
0.23%
3/1308 • 5 years
Infections and infestations
OTITIS MEDIA CHRONIC
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
PELVIC INFECTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
PERIUMBILICAL ABSCESS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
PHARYNGEAL ABSCESS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
PHARYNGITIS
0.00%
0/1296 • 5 years
0.23%
3/1308 • 5 years
Infections and infestations
PHARYNGITIS BACTERIAL
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
PHARYNGITIS STREPTOCOCCAL
0.00%
0/1296 • 5 years
0.23%
3/1308 • 5 years
Infections and infestations
PLEURAL INFECTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Investigations
HEART RATE DECREASED
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Musculoskeletal and connective tissue disorders
OSTEOARTHRITIS
2.7%
35/1296 • 5 years
2.4%
31/1308 • 5 years
Musculoskeletal and connective tissue disorders
OSTEOCHONDROSIS
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Musculoskeletal and connective tissue disorders
OSTEONECROSIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Musculoskeletal and connective tissue disorders
OSTEOPOROSIS
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Musculoskeletal and connective tissue disorders
OSTEOSCLEROSIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Musculoskeletal and connective tissue disorders
PAIN IN EXTREMITY
1.7%
22/1296 • 5 years
2.8%
36/1308 • 5 years
Musculoskeletal and connective tissue disorders
PAIN IN JAW
0.39%
5/1296 • 5 years
0.08%
1/1308 • 5 years
Musculoskeletal and connective tissue disorders
PERIARTHRITIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Musculoskeletal and connective tissue disorders
PLANTAR FASCIAL FIBROMATOSIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Musculoskeletal and connective tissue disorders
PLANTAR FASCIITIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Musculoskeletal and connective tissue disorders
POLYMYALGIA RHEUMATICA
0.15%
2/1296 • 5 years
0.15%
2/1308 • 5 years
Musculoskeletal and connective tissue disorders
PSEUDARTHROSIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Musculoskeletal and connective tissue disorders
PSORIATIC ARTHROPATHY
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Musculoskeletal and connective tissue disorders
RHABDOMYOLYSIS
0.23%
3/1296 • 5 years
0.00%
0/1308 • 5 years
Congenital, familial and genetic disorders
GASTROINTESTINAL ARTERIOVENOUS MALFORMATION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Congenital, familial and genetic disorders
HYDROCELE
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Blood and lymphatic system disorders
ANAEMIA
1.8%
23/1296 • 5 years
2.2%
29/1308 • 5 years
Blood and lymphatic system disorders
FEBRILE NEUTROPENIA
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Blood and lymphatic system disorders
HAEMORRHAGIC ANAEMIA
0.23%
3/1296 • 5 years
0.15%
2/1308 • 5 years
Blood and lymphatic system disorders
HAEMORRHAGIC DIATHESIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Blood and lymphatic system disorders
IRON DEFICIENCY ANAEMIA
0.54%
7/1296 • 5 years
0.69%
9/1308 • 5 years
Blood and lymphatic system disorders
LEUKOCYTOSIS
0.00%
0/1296 • 5 years
0.38%
5/1308 • 5 years
Blood and lymphatic system disorders
LYMPHADENOPATHY
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Blood and lymphatic system disorders
NEUTROPENIA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Blood and lymphatic system disorders
NORMOCHROMIC NORMOCYTIC ANAEMIA
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Blood and lymphatic system disorders
PANCYTOPENIA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Blood and lymphatic system disorders
SPLENIC GRANULOMA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Blood and lymphatic system disorders
THROMBOCYTOPENIA
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
ACCELERATED IDIOVENTRICULAR RHYTHM
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
ACUTE CORONARY SYNDROME
0.77%
10/1296 • 5 years
0.61%
8/1308 • 5 years
Cardiac disorders
ACUTE LEFT VENTRICULAR FAILURE
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
ACUTE MYOCARDIAL INFARCTION
2.2%
28/1296 • 5 years
2.1%
28/1308 • 5 years
Cardiac disorders
ANGINA PECTORIS
26.4%
342/1296 • 5 years
25.4%
332/1308 • 5 years
Cardiac disorders
ANGINA UNSTABLE
4.7%
61/1296 • 5 years
5.4%
70/1308 • 5 years
Cardiac disorders
AORTIC VALVE INCOMPETENCE
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
AORTIC VALVE STENOSIS
0.15%
2/1296 • 5 years
0.31%
4/1308 • 5 years
Cardiac disorders
ARRHYTHMIA
0.31%
4/1296 • 5 years
0.31%
4/1308 • 5 years
Cardiac disorders
ARTERIOSCLEROSIS CORONARY ARTERY
0.31%
4/1296 • 5 years
0.23%
3/1308 • 5 years
Cardiac disorders
ARTERIOSPASM CORONARY
0.00%
0/1296 • 5 years
0.23%
3/1308 • 5 years
Cardiac disorders
ATRIAL FIBRILLATION
6.0%
78/1296 • 5 years
4.4%
57/1308 • 5 years
Cardiac disorders
ATRIAL FLUTTER
0.31%
4/1296 • 5 years
0.46%
6/1308 • 5 years
Cardiac disorders
ATRIAL TACHYCARDIA
0.23%
3/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
ATRIAL THROMBOSIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
ATRIOVENTRICULAR BLOCK
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
ATRIOVENTRICULAR BLOCK COMPLETE
0.15%
2/1296 • 5 years
0.23%
3/1308 • 5 years
Cardiac disorders
ATRIOVENTRICULAR BLOCK SECOND DEGREE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
BRADYCARDIA
1.6%
21/1296 • 5 years
1.2%
16/1308 • 5 years
Cardiac disorders
BUNDLE BRANCH BLOCK LEFT
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Cardiac disorders
BUNDLE BRANCH BLOCK RIGHT
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
CARDIAC ANEURYSM
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
CARDIAC ARREST
0.77%
10/1296 • 5 years
0.31%
4/1308 • 5 years
Cardiac disorders
CARDIAC FAILURE
1.2%
16/1296 • 5 years
0.38%
5/1308 • 5 years
Cardiac disorders
CARDIAC FAILURE ACUTE
0.46%
6/1296 • 5 years
0.46%
6/1308 • 5 years
Cardiac disorders
CARDIAC FAILURE CHRONIC
0.39%
5/1296 • 5 years
0.15%
2/1308 • 5 years
Cardiac disorders
CARDIAC FAILURE CONGESTIVE
2.5%
33/1296 • 5 years
2.2%
29/1308 • 5 years
Cardiac disorders
CARDIAC FLUTTER
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
CARDIAC PERFORATION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
CARDIAC TAMPONADE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
CARDIAC VALVE DISEASE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
CARDIO-RESPIRATORY ARREST
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Cardiac disorders
CARDIOGENIC SHOCK
0.39%
5/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
CARDIOMYOPATHY
0.23%
3/1296 • 5 years
0.23%
3/1308 • 5 years
Cardiac disorders
CARDIOPULMONARY FAILURE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
CARDIOVASCULAR DISORDER
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
CHRONOTROPIC INCOMPETENCE
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
CONGESTIVE CARDIOMYOPATHY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
COR PULMONALE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
CORONARY ARTERY ANEURYSM
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
CORONARY ARTERY DISEASE
3.8%
49/1296 • 5 years
3.6%
47/1308 • 5 years
Cardiac disorders
CORONARY ARTERY DISSECTION
7.1%
92/1296 • 5 years
4.8%
63/1308 • 5 years
Cardiac disorders
CORONARY ARTERY EMBOLISM
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
CORONARY ARTERY OCCLUSION
0.62%
8/1296 • 5 years
0.31%
4/1308 • 5 years
Cardiac disorders
CORONARY ARTERY PERFORATION
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
CORONARY ARTERY STENOSIS
1.2%
16/1296 • 5 years
1.3%
17/1308 • 5 years
Cardiac disorders
CORONARY ARTERY THROMBOSIS
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
CYANOSIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
DIASTOLIC DYSFUNCTION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
EXTRASYSTOLES
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
HEART VALVE INCOMPETENCE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
HYPERTENSIVE HEART DISEASE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
HYPERTROPHIC CARDIOMYOPATHY
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
IN-STENT CORONARY ARTERY RESTENOSIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
INTRACARDIAC THROMBUS
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
INTRAPERICARDIAL THROMBOSIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
ISCHAEMIC CARDIOMYOPATHY
0.39%
5/1296 • 5 years
0.69%
9/1308 • 5 years
Cardiac disorders
LEFT VENTRICULAR DYSFUNCTION
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
LEFT VENTRICULAR HYPERTROPHY
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
MICROVASCULAR ANGINA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
MITRAL VALVE INCOMPETENCE
0.54%
7/1296 • 5 years
0.15%
2/1308 • 5 years
Cardiac disorders
MITRAL VALVE PROLAPSE
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
MITRAL VALVE STENOSIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
MYOCARDIAL INFARCTION
5.8%
75/1296 • 5 years
4.5%
59/1308 • 5 years
Cardiac disorders
MYOCARDIAL ISCHAEMIA
0.77%
10/1296 • 5 years
0.46%
6/1308 • 5 years
Cardiac disorders
MYOCARDITIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
MYOPERICARDITIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
NODAL ARRHYTHMIA
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Cardiac disorders
PALPITATIONS
2.2%
28/1296 • 5 years
2.6%
34/1308 • 5 years
Cardiac disorders
PERICARDIAL EFFUSION
0.15%
2/1296 • 5 years
0.15%
2/1308 • 5 years
Cardiac disorders
PERICARDIAL HAEMORRHAGE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
PERICARDITIS
0.31%
4/1296 • 5 years
0.46%
6/1308 • 5 years
Cardiac disorders
PRINZMETAL ANGINA
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
PULSELESS ELECTRICAL ACTIVITY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
RESTRICTIVE CARDIOMYOPATHY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
SICK SINUS SYNDROME
0.46%
6/1296 • 5 years
0.31%
4/1308 • 5 years
Cardiac disorders
SINUS ARREST
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
SINUS BRADYCARDIA
0.31%
4/1296 • 5 years
0.23%
3/1308 • 5 years
Cardiac disorders
SINUS TACHYCARDIA
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
STRESS CARDIOMYOPATHY
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
SUPRAVENTRICULAR EXTRASYSTOLES
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
SUPRAVENTRICULAR TACHYCARDIA
0.39%
5/1296 • 5 years
0.61%
8/1308 • 5 years
Cardiac disorders
TACHYARRHYTHMIA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Congenital, familial and genetic disorders
PERONEAL MUSCULAR ATROPHY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
TACHYCARDIA
0.62%
8/1296 • 5 years
0.38%
5/1308 • 5 years
Cardiac disorders
TRICUSPID VALVE INCOMPETENCE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Cardiac disorders
VENTRICULAR ARRHYTHMIA
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Cardiac disorders
VENTRICULAR EXTRASYSTOLES
0.46%
6/1296 • 5 years
0.31%
4/1308 • 5 years
Cardiac disorders
VENTRICULAR FIBRILLATION
0.46%
6/1296 • 5 years
0.08%
1/1308 • 5 years
Cardiac disorders
VENTRICULAR TACHYCARDIA
1.1%
14/1296 • 5 years
0.76%
10/1308 • 5 years
Congenital, familial and genetic disorders
ARTERIOVENOUS MALFORMATION
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Congenital, familial and genetic disorders
ATRIAL SEPTAL DEFECT
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Congenital, familial and genetic disorders
CORNEAL DYSTROPHY
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Ear and labyrinth disorders
DEAFNESS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Ear and labyrinth disorders
DEAFNESS UNILATERAL
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Ear and labyrinth disorders
EAR CONGESTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Ear and labyrinth disorders
EAR HAEMORRHAGE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Ear and labyrinth disorders
EAR PAIN
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Ear and labyrinth disorders
EUSTACHIAN TUBE DYSFUNCTION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Ear and labyrinth disorders
NEUROSENSORY HYPOACUSIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Ear and labyrinth disorders
TINNITUS
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Ear and labyrinth disorders
TYMPANIC MEMBRANE PERFORATION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Ear and labyrinth disorders
VERTIGO
0.62%
8/1296 • 5 years
1.1%
14/1308 • 5 years
Ear and labyrinth disorders
VERTIGO POSITIONAL
0.15%
2/1296 • 5 years
0.31%
4/1308 • 5 years
Endocrine disorders
ADRENAL INSUFFICIENCY
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Endocrine disorders
ADRENAL MASS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Endocrine disorders
CARCINOID SYNDROME
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Endocrine disorders
GOITRE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Endocrine disorders
HYPERPARATHYROIDISM
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Endocrine disorders
HYPERTHYROIDISM
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Endocrine disorders
HYPOGONADISM
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Endocrine disorders
HYPOTHYROIDIC GOITRE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Endocrine disorders
HYPOTHYROIDISM
0.08%
1/1296 • 5 years
0.31%
4/1308 • 5 years
Endocrine disorders
SECONDARY HYPOGONADISM
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Endocrine disorders
THYROID MASS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Eye disorders
ABNORMAL SENSATION IN EYE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Eye disorders
AGE-RELATED MACULAR DEGENERATION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Eye disorders
AMAUROSIS FUGAX
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Eye disorders
BLINDNESS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Eye disorders
BLINDNESS TRANSIENT
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Eye disorders
CATARACT
0.77%
10/1296 • 5 years
0.61%
8/1308 • 5 years
Eye disorders
CONJUNCTIVAL HAEMORRHAGE
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Eye disorders
CONJUNCTIVITIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Eye disorders
DIABETIC RETINOPATHY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Eye disorders
DIPLOPIA
0.08%
1/1296 • 5 years
0.23%
3/1308 • 5 years
Eye disorders
DRY EYE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Eye disorders
EYE HAEMORRHAGE
0.15%
2/1296 • 5 years
0.15%
2/1308 • 5 years
Eye disorders
EYE PAIN
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Eye disorders
GLAUCOMA
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Eye disorders
LACRIMAL DISORDER
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Eye disorders
MACULAR DEGENERATION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Eye disorders
MACULAR FIBROSIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Eye disorders
MACULAR OEDEMA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Eye disorders
OCULAR HYPERAEMIA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Eye disorders
RETINAL ARTERY EMBOLISM
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Eye disorders
RETINAL DETACHMENT
0.00%
0/1296 • 5 years
0.23%
3/1308 • 5 years
Eye disorders
RETINAL DISORDER
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Eye disorders
RETINAL TEAR
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Eye disorders
RETINOPATHY PROLIFERATIVE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Eye disorders
TOLOSA-HUNT SYNDROME
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Eye disorders
VISION BLURRED
0.15%
2/1296 • 5 years
0.38%
5/1308 • 5 years
Eye disorders
VISUAL IMPAIRMENT
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Eye disorders
VITREOUS DETACHMENT
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Eye disorders
VITREOUS HAEMORRHAGE
0.00%
0/1296 • 5 years
0.23%
3/1308 • 5 years
Gastrointestinal disorders
ABDOMINAL DISCOMFORT
0.15%
2/1296 • 5 years
0.31%
4/1308 • 5 years
Gastrointestinal disorders
ABDOMINAL DISTENSION
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
ABDOMINAL HERNIA
0.23%
3/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
ABDOMINAL MASS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
ABDOMINAL PAIN
1.2%
15/1296 • 5 years
1.4%
18/1308 • 5 years
Gastrointestinal disorders
ABDOMINAL PAIN LOWER
0.08%
1/1296 • 5 years
0.23%
3/1308 • 5 years
Gastrointestinal disorders
ABDOMINAL PAIN UPPER
1.2%
16/1296 • 5 years
0.54%
7/1308 • 5 years
Gastrointestinal disorders
ANAL FISSURE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
ANAL HAEMORRHAGE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
APPENDIX DISORDER
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
ASCITES
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
BARRETT'S OESOPHAGUS
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Gastrointestinal disorders
BOWEL MOVEMENT IRREGULARITY
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
CHRONIC GASTROINTESTINAL BLEEDING
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
COLITIS
0.54%
7/1296 • 5 years
0.38%
5/1308 • 5 years
Gastrointestinal disorders
COLITIS ISCHAEMIC
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Gastrointestinal disorders
COLITIS ULCERATIVE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
COLONIC POLYP
0.39%
5/1296 • 5 years
0.61%
8/1308 • 5 years
Gastrointestinal disorders
CONSTIPATION
0.46%
6/1296 • 5 years
0.76%
10/1308 • 5 years
Gastrointestinal disorders
CROHN'S DISEASE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
DENTAL CARIES
0.23%
3/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
DIARRHOEA
1.4%
18/1296 • 5 years
1.5%
20/1308 • 5 years
Gastrointestinal disorders
DIVERTICULAR PERFORATION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
DIVERTICULITIS INTESTINAL HAEMORRHAGIC
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Gastrointestinal disorders
DIVERTICULUM
0.15%
2/1296 • 5 years
0.31%
4/1308 • 5 years
Gastrointestinal disorders
DIVERTICULUM INTESTINAL
0.15%
2/1296 • 5 years
0.54%
7/1308 • 5 years
Gastrointestinal disorders
DIVERTICULUM INTESTINAL HAEMORRHAGIC
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
DUODENAL PERFORATION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
DUODENAL ULCER
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
DUODENAL ULCER PERFORATION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
DUODENITIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
DYSPEPSIA
0.85%
11/1296 • 5 years
0.84%
11/1308 • 5 years
Gastrointestinal disorders
DYSPHAGIA
0.39%
5/1296 • 5 years
0.38%
5/1308 • 5 years
Gastrointestinal disorders
ENTERITIS
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
ENTEROCOLITIS HAEMORRHAGIC
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
ENTEROVESICAL FISTULA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
EPIGASTRIC DISCOMFORT
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
EROSIVE OESOPHAGITIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
ERUCTATION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
FAECALOMA
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
FAECES DISCOLOURED
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
FLATULENCE
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Gastrointestinal disorders
FOOD POISONING
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
GASTRIC DISORDER
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Gastrointestinal disorders
GASTRIC POLYPS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
GASTRIC ULCER
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Gastrointestinal disorders
GASTRIC ULCER HAEMORRHAGE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
GASTRITIS
0.54%
7/1296 • 5 years
0.76%
10/1308 • 5 years
Gastrointestinal disorders
GASTRITIS EROSIVE
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Gastrointestinal disorders
GASTRITIS HAEMORRHAGIC
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
GASTROINTESTINAL HAEMORRHAGE
1.3%
17/1296 • 5 years
0.99%
13/1308 • 5 years
Gastrointestinal disorders
GASTROINTESTINAL MOTILITY DISORDER
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
GASTROINTESTINAL MUCOSAL DISORDER
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
GASTROINTESTINAL MUCOSAL EXFOLIATION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
GASTROINTESTINAL ULCER HAEMORRHAGE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
GASTROOESOPHAGEAL REFLUX DISEASE
1.5%
19/1296 • 5 years
1.2%
16/1308 • 5 years
Gastrointestinal disorders
GINGIVAL BLEEDING
0.15%
2/1296 • 5 years
0.15%
2/1308 • 5 years
Gastrointestinal disorders
GINGIVAL DISORDER
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
HAEMATEMESIS
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Gastrointestinal disorders
HAEMATOCHEZIA
0.46%
6/1296 • 5 years
0.31%
4/1308 • 5 years
Gastrointestinal disorders
HAEMORRHOIDAL HAEMORRHAGE
0.00%
0/1296 • 5 years
0.31%
4/1308 • 5 years
Gastrointestinal disorders
HAEMORRHOIDS
0.08%
1/1296 • 5 years
0.31%
4/1308 • 5 years
Gastrointestinal disorders
HIATUS HERNIA
0.39%
5/1296 • 5 years
0.23%
3/1308 • 5 years
Gastrointestinal disorders
ILEUS
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Gastrointestinal disorders
IMPAIRED GASTRIC EMPTYING
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
INGUINAL HERNIA
1.1%
14/1296 • 5 years
0.61%
8/1308 • 5 years
Gastrointestinal disorders
INGUINAL HERNIA, OBSTRUCTIVE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
INTESTINAL MASS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
IRRITABLE BOWEL SYNDROME
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
LARGE INTESTINE PERFORATION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
LIP HAEMORRHAGE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
LIP SWELLING
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
LOWER GASTROINTESTINAL HAEMORRHAGE
0.23%
3/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
MALLORY-WEISS SYNDROME
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
MELAENA
0.23%
3/1296 • 5 years
0.23%
3/1308 • 5 years
Gastrointestinal disorders
MELANOSIS COLI
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
MESENTERIC HAEMORRHAGE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
MOUTH HAEMORRHAGE
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
MOUTH ULCERATION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
NAUSEA
2.6%
34/1296 • 5 years
2.7%
35/1308 • 5 years
Gastrointestinal disorders
OBSTRUCTION GASTRIC
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
ODYNOPHAGIA
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
OESOPHAGEAL HYPOMOTILITY
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
OESOPHAGEAL SPASM
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
OESOPHAGEAL STENOSIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
OESOPHAGITIS
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Gastrointestinal disorders
ORAL MUCOSAL DISCOLOURATION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
PANCREATIC MASS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
PANCREATITIS
0.08%
1/1296 • 5 years
0.46%
6/1308 • 5 years
Gastrointestinal disorders
PANCREATITIS ACUTE
0.08%
1/1296 • 5 years
0.38%
5/1308 • 5 years
Gastrointestinal disorders
PANCREATITIS CHRONIC
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Gastrointestinal disorders
PARAESTHESIA ORAL
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
POLYP COLORECTAL
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
PROCTALGIA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
PROCTITIS
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
PROCTITIS ULCERATIVE
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
RECTAL HAEMORRHAGE
0.62%
8/1296 • 5 years
0.84%
11/1308 • 5 years
Gastrointestinal disorders
RECTAL POLYP
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Gastrointestinal disorders
RETROPERITONEAL HAEMORRHAGE
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
SALIVARY GLAND MASS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
SMALL INTESTINAL OBSTRUCTION
0.77%
10/1296 • 5 years
0.46%
6/1308 • 5 years
Gastrointestinal disorders
SPIGELIAN HERNIA
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Gastrointestinal disorders
STOMACH MASS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
STOMATITIS
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Gastrointestinal disorders
SWOLLEN TONGUE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
TOOTH DISORDER
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Gastrointestinal disorders
TOOTH LOSS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
TOOTHACHE
0.15%
2/1296 • 5 years
0.15%
2/1308 • 5 years
Gastrointestinal disorders
UMBILICAL HERNIA
0.23%
3/1296 • 5 years
0.31%
4/1308 • 5 years
Gastrointestinal disorders
UPPER GASTROINTESTINAL HAEMORRHAGE
0.54%
7/1296 • 5 years
0.15%
2/1308 • 5 years
Gastrointestinal disorders
VOLVULUS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Gastrointestinal disorders
VOMITING
0.39%
5/1296 • 5 years
0.46%
6/1308 • 5 years
General disorders
ADVERSE DRUG REACTION
6.0%
78/1296 • 5 years
5.7%
75/1308 • 5 years
General disorders
ASTHENIA
2.1%
27/1296 • 5 years
1.6%
21/1308 • 5 years
General disorders
AXILLARY PAIN
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
CARDIAC COMPLICATION ASSOCIATED WITH DEVICE
0.23%
3/1296 • 5 years
0.00%
0/1308 • 5 years
General disorders
CARDIAC DEATH
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
General disorders
CATHETER SITE HAEMATOMA
2.0%
26/1296 • 5 years
2.4%
32/1308 • 5 years
General disorders
CATHETER SITE HAEMORRHAGE
0.62%
8/1296 • 5 years
1.2%
16/1308 • 5 years
General disorders
CATHETER SITE NECROSIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
CATHETER SITE PAIN
0.69%
9/1296 • 5 years
1.6%
21/1308 • 5 years
General disorders
CATHETER SITE RASH
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
General disorders
CATHETER SITE RELATED REACTION
0.00%
0/1296 • 5 years
0.23%
3/1308 • 5 years
General disorders
CATHETER SITE SWELLING
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
CHEST DISCOMFORT
4.6%
60/1296 • 5 years
5.0%
65/1308 • 5 years
General disorders
CHEST PAIN
8.1%
105/1296 • 5 years
8.4%
110/1308 • 5 years
General disorders
CHILLS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
COMPLICATION OF DEVICE REMOVAL
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
General disorders
CYST
0.00%
0/1296 • 5 years
0.46%
6/1308 • 5 years
General disorders
DEATH
0.54%
7/1296 • 5 years
0.84%
11/1308 • 5 years
General disorders
DEVICE BREAKAGE
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
DEVICE FAILURE
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
General disorders
DEVICE ISSUE
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
DEVICE MALFUNCTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
General disorders
DEVICE MATERIAL ISSUE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
DEVICE OCCLUSION
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
DISEASE PROGRESSION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
DRUG INTOLERANCE
0.15%
2/1296 • 5 years
0.15%
2/1308 • 5 years
General disorders
EARLY SATIETY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
EXERCISE TOLERANCE DECREASED
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
General disorders
FACIAL PAIN
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
FATIGUE
3.5%
45/1296 • 5 years
3.3%
43/1308 • 5 years
General disorders
FEELING COLD
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
General disorders
FEELING HOT
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
GAIT DISTURBANCE
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
GENERAL PHYSICAL HEALTH DETERIORATION
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
General disorders
GENERALISED OEDEMA
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
GRANULOMA
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
General disorders
HERNIA
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
General disorders
HYPERTHERMIA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
General disorders
IMPAIRED HEALING
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
General disorders
INFLAMMATION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
General disorders
INFLUENZA LIKE ILLNESS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
General disorders
INFUSION SITE PAIN
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
LOCAL SWELLING
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
MALAISE
0.69%
9/1296 • 5 years
0.76%
10/1308 • 5 years
General disorders
MEDICAL DEVICE COMPLICATION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
MEDICAL DEVICE PAIN
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
General disorders
MEDICAL DEVICE SITE REACTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
General disorders
METAPLASIA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
MULTI-ORGAN FAILURE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
NON-CARDIAC CHEST PAIN
17.7%
230/1296 • 5 years
20.9%
274/1308 • 5 years
General disorders
OEDEMA
0.08%
1/1296 • 5 years
0.23%
3/1308 • 5 years
General disorders
OEDEMA PERIPHERAL
2.1%
27/1296 • 5 years
1.7%
22/1308 • 5 years
General disorders
PACEMAKER GENERATED ARRHYTHMIA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
General disorders
PAIN
0.15%
2/1296 • 5 years
0.69%
9/1308 • 5 years
General disorders
PATIENT-DEVICE INCOMPATIBILITY
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
General disorders
PYREXIA
0.69%
9/1296 • 5 years
0.23%
3/1308 • 5 years
General disorders
SENSATION OF FOREIGN BODY
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
SPINAL PAIN
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
General disorders
STENT-GRAFT ENDOLEAK
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
SUDDEN CARDIAC DEATH
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
SWELLING
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
SYSTEMIC INFLAMMATORY RESPONSE SYNDROME
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
General disorders
THROMBOSIS IN DEVICE
1.0%
13/1296 • 5 years
0.99%
13/1308 • 5 years
General disorders
ULCER
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
General disorders
UNEVALUABLE EVENT
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
General disorders
VESSEL PUNCTURE SITE HAEMATOMA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
General disorders
VESSEL PUNCTURE SITE THROMBOSIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Hepatobiliary disorders
ACUTE HEPATIC FAILURE
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Hepatobiliary disorders
BILE DUCT OBSTRUCTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Hepatobiliary disorders
BILE DUCT STONE
0.23%
3/1296 • 5 years
0.31%
4/1308 • 5 years
Hepatobiliary disorders
BILIARY COLIC
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Hepatobiliary disorders
BILIARY DILATATION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Hepatobiliary disorders
BILIARY DYSKINESIA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Hepatobiliary disorders
CHOLANGITIS
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Hepatobiliary disorders
CHOLANGITIS ACUTE
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Hepatobiliary disorders
CHOLECYSTITIS
0.31%
4/1296 • 5 years
0.23%
3/1308 • 5 years
Hepatobiliary disorders
CHOLECYSTITIS ACUTE
0.23%
3/1296 • 5 years
0.23%
3/1308 • 5 years
Hepatobiliary disorders
CHOLECYSTITIS CHRONIC
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Hepatobiliary disorders
CHOLELITHIASIS
0.77%
10/1296 • 5 years
0.46%
6/1308 • 5 years
Hepatobiliary disorders
CIRRHOSIS ALCOHOLIC
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Hepatobiliary disorders
GALLBLADDER DISORDER
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Hepatobiliary disorders
GRANULOMATOUS LIVER DISEASE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Hepatobiliary disorders
HEPATIC CIRRHOSIS
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Hepatobiliary disorders
HEPATIC CYST
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Hepatobiliary disorders
HEPATIC FAILURE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Hepatobiliary disorders
HEPATIC FUNCTION ABNORMAL
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Hepatobiliary disorders
HEPATIC LESION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Hepatobiliary disorders
HEPATIC PAIN
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Hepatobiliary disorders
HEPATIC STEATOSIS
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Hepatobiliary disorders
HEPATORENAL FAILURE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Hepatobiliary disorders
ISCHAEMIC HEPATITIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Hepatobiliary disorders
JAUNDICE
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Hepatobiliary disorders
JAUNDICE CHOLESTATIC
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Hepatobiliary disorders
NON-ALCOHOLIC STEATOHEPATITIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Immune system disorders
ALLERGY TO ARTHROPOD BITE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Immune system disorders
ALLERGY TO ARTHROPOD STING
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Immune system disorders
AMYLOIDOSIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Immune system disorders
ANAPHYLACTIC REACTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Immune system disorders
CONTRAST MEDIA ALLERGY
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Immune system disorders
DRUG HYPERSENSITIVITY
0.46%
6/1296 • 5 years
0.15%
2/1308 • 5 years
Immune system disorders
FOOD ALLERGY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Immune system disorders
HYPERSENSITIVITY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Immune system disorders
SARCOIDOSIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Immune system disorders
SEASONAL ALLERGY
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
ABDOMINAL ABSCESS
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Infections and infestations
ABDOMINAL SEPSIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
ABSCESS LIMB
0.15%
2/1296 • 5 years
0.23%
3/1308 • 5 years
Infections and infestations
ABSCESS NECK
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
ABSCESS OF SALIVARY GLAND
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
ABSCESS ORAL
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
ACARODERMATITIS
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
ACUTE SINUSITIS
0.39%
5/1296 • 5 years
0.38%
5/1308 • 5 years
Infections and infestations
APPENDICITIS
0.31%
4/1296 • 5 years
0.31%
4/1308 • 5 years
Infections and infestations
ARTERIOVENOUS GRAFT SITE INFECTION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
ARTHRITIS INFECTIVE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
BACTERAEMIA
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
BACTERIAL INFECTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
BACTERIAL SEPSIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
BODY TINEA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
BRONCHIOLITIS
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
BRONCHITIS
1.8%
23/1296 • 5 years
1.5%
20/1308 • 5 years
Infections and infestations
BRONCHITIS VIRAL
0.00%
0/1296 • 5 years
0.23%
3/1308 • 5 years
Infections and infestations
BRONCHOPNEUMONIA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
BURSITIS INFECTIVE
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
CAMPYLOBACTER INFECTION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
CATHETER SITE ABSCESS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
CATHETER SITE CELLULITIS
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
CELLULITIS
1.2%
15/1296 • 5 years
1.1%
14/1308 • 5 years
Infections and infestations
CELLULITIS OF MALE EXTERNAL GENITAL ORGAN
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
CHOLECYSTITIS INFECTIVE
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Infections and infestations
CHRONIC SINUSITIS
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Infections and infestations
CLOSTRIDIAL INFECTION
0.15%
2/1296 • 5 years
0.23%
3/1308 • 5 years
Infections and infestations
CLOSTRIDIUM COLITIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
CLOSTRIDIUM DIFFICILE COLITIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
CONJUNCTIVITIS BACTERIAL
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
CORONA VIRUS INFECTION
1.1%
14/1296 • 5 years
0.31%
4/1308 • 5 years
Infections and infestations
CYSTITIS
0.15%
2/1296 • 5 years
0.23%
3/1308 • 5 years
Infections and infestations
DEVICE RELATED INFECTION
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
DIABETIC FOOT INFECTION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
DIVERTICULITIS
1.4%
18/1296 • 5 years
1.1%
14/1308 • 5 years
Infections and infestations
EAR INFECTION
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Infections and infestations
EMPYEMA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
ENDOCARDITIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
ENDOMETRITIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
ENTEROCOCCAL BACTERAEMIA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
ENTEROCOLITIS INFECTIOUS
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
EPIDEMIC POLYARTHRITIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
ESCHERICHIA BACTERAEMIA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
ESCHERICHIA INFECTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
ESCHERICHIA SEPSIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
ESCHERICHIA URINARY TRACT INFECTION
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Infections and infestations
EXTRADURAL ABSCESS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
FURUNCLE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
GANGRENE
0.23%
3/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
GASTRIC INFECTION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
GASTRITIS VIRAL
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
GASTROENTERITIS
0.54%
7/1296 • 5 years
0.61%
8/1308 • 5 years
Infections and infestations
GASTROENTERITIS VIRAL
0.31%
4/1296 • 5 years
0.15%
2/1308 • 5 years
Infections and infestations
GASTROINTESTINAL INFECTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
GENITAL HERPES
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
HELICOBACTER GASTRITIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
HELICOBACTER INFECTION
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Infections and infestations
HEPATITIS C
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
HERPES SIMPLEX
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
HERPES ZOSTER
0.46%
6/1296 • 5 years
0.61%
8/1308 • 5 years
Infections and infestations
HERPES ZOSTER OTICUS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
IMPETIGO
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
IMPLANT SITE INFECTION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
INCISION SITE INFECTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
INFECTED BITES
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
INFECTED CYST
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
INFECTED DERMAL CYST
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
INFECTED SKIN ULCER
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
INFECTIOUS PLEURAL EFFUSION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
INFLUENZA
1.0%
13/1296 • 5 years
1.5%
20/1308 • 5 years
Infections and infestations
INTERTRIGO CANDIDA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
KIDNEY INFECTION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
KLEBSIELLA BACTERAEMIA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
KLEBSIELLA SEPSIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
LABYRINTHITIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
LARYNGITIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
LIVER ABSCESS
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
LOBAR PNEUMONIA
0.46%
6/1296 • 5 years
0.38%
5/1308 • 5 years
Infections and infestations
LOCALISED INFECTION
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
LOWER RESPIRATORY TRACT INFECTION
0.23%
3/1296 • 5 years
0.31%
4/1308 • 5 years
Infections and infestations
LUNG INFECTION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
LUNG INFECTION PSEUDOMONAL
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
LYME DISEASE
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
LYMPH GLAND INFECTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
MUSCLE ABSCESS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
MYRINGITIS BULLOUS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
NASOPHARYNGITIS
0.69%
9/1296 • 5 years
0.92%
12/1308 • 5 years
Infections and infestations
NECROTISING FASCIITIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
OESOPHAGEAL CANDIDIASIS
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Infections and infestations
ORAL CANDIDIASIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
ORAL FUNGAL INFECTION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
ORCHITIS
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
OSTEOMYELITIS
0.00%
0/1296 • 5 years
0.38%
5/1308 • 5 years
Infections and infestations
OSTEOMYELITIS CHRONIC
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
OTITIS EXTERNA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
OTITIS MEDIA
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
OTITIS MEDIA ACUTE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
PNEUMONIA
3.2%
42/1296 • 5 years
3.2%
42/1308 • 5 years
Infections and infestations
PNEUMONIA ESCHERICHIA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
PNEUMONIA KLEBSIELLA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
PNEUMONIA STREPTOCOCCAL
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
PNEUMONIA VIRAL
0.08%
1/1296 • 5 years
0.31%
4/1308 • 5 years
Infections and infestations
POST PROCEDURAL CELLULITIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
POSTOPERATIVE ABSCESS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
POSTOPERATIVE WOUND INFECTION
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
PYELONEPHRITIS
0.15%
2/1296 • 5 years
0.23%
3/1308 • 5 years
Infections and infestations
PYELONEPHRITIS ACUTE
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
RESPIRATORY TRACT INFECTION
0.15%
2/1296 • 5 years
0.15%
2/1308 • 5 years
Infections and infestations
RESPIRATORY TRACT INFECTION VIRAL
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
RHINOVIRUS INFECTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
SCROTAL ABSCESS
0.23%
3/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
SEPSIS
1.5%
20/1296 • 5 years
1.1%
14/1308 • 5 years
Infections and infestations
SEPSIS SYNDROME
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
SEPTIC ENCEPHALOPATHY
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
SEPTIC SHOCK
0.15%
2/1296 • 5 years
0.31%
4/1308 • 5 years
Infections and infestations
SIALOADENITIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
SINOBRONCHITIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
SINUSITIS
0.85%
11/1296 • 5 years
0.76%
10/1308 • 5 years
Infections and infestations
SINUSITIS BACTERIAL
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
SKIN INFECTION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
STAPHYLOCOCCAL ABSCESS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
STAPHYLOCOCCAL BACTERAEMIA
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
STAPHYLOCOCCAL INFECTION
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
STAPHYLOCOCCAL SEPSIS
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
SUBCUTANEOUS ABSCESS
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Infections and infestations
TESTICULAR ABSCESS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
TINEA PEDIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
TOOTH ABSCESS
0.23%
3/1296 • 5 years
0.46%
6/1308 • 5 years
Infections and infestations
TOOTH INFECTION
0.23%
3/1296 • 5 years
0.38%
5/1308 • 5 years
Infections and infestations
TRICHOMONIASIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
UPPER RESPIRATORY TRACT INFECTION
1.5%
20/1296 • 5 years
1.8%
24/1308 • 5 years
Infections and infestations
UPPER RESPIRATORY TRACT INFECTION BACTERIAL
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
URETHRITIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
URINARY TRACT INFECTION
1.9%
24/1296 • 5 years
2.5%
33/1308 • 5 years
Infections and infestations
URINARY TRACT INFECTION BACTERIAL
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
UROSEPSIS
0.39%
5/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
VAGINITIS BACTERIAL
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
VESTIBULAR NEURONITIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
VIRAL INFECTION
0.23%
3/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
VIRAL LABYRINTHITIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
VIRAL UPPER RESPIRATORY TRACT INFECTION
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Infections and infestations
WEST NILE VIRAL INFECTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
WOUND INFECTION
0.15%
2/1296 • 5 years
0.23%
3/1308 • 5 years
Infections and infestations
WOUND INFECTION BACTERIAL
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Infections and infestations
WOUND INFECTION STAPHYLOCOCCAL
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
ACCIDENTAL OVERDOSE
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Injury, poisoning and procedural complications
ACETABULUM FRACTURE
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
ADRENAL GLAND INJURY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
ALCOHOL POISONING
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
ANAEMIA POSTOPERATIVE
0.23%
3/1296 • 5 years
0.15%
2/1308 • 5 years
Injury, poisoning and procedural complications
ANASTOMOTIC LEAK
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
ANASTOMOTIC ULCER HAEMORRHAGE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
ANIMAL BITE
0.00%
0/1296 • 5 years
0.31%
4/1308 • 5 years
Injury, poisoning and procedural complications
ANKLE FRACTURE
0.23%
3/1296 • 5 years
0.76%
10/1308 • 5 years
Injury, poisoning and procedural complications
ARTERIAL INJURY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
ARTHROPOD BITE
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
ARTHROPOD STING
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
ASBESTOSIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
AXILLARY NERVE INJURY
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
BACK INJURY
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
CARDIAC PROCEDURE COMPLICATION
0.54%
7/1296 • 5 years
0.23%
3/1308 • 5 years
Injury, poisoning and procedural complications
CATHETER SITE HAEMATOMA
0.23%
3/1296 • 5 years
0.46%
6/1308 • 5 years
Injury, poisoning and procedural complications
CERVICAL VERTEBRAL FRACTURE
0.15%
2/1296 • 5 years
0.15%
2/1308 • 5 years
Injury, poisoning and procedural complications
COMMINUTED FRACTURE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
CONCUSSION
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
CONFUSION POSTOPERATIVE
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
CONTRAST MEDIA ALLERGY
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
CONTUSION
1.2%
16/1296 • 5 years
1.7%
22/1308 • 5 years
Injury, poisoning and procedural complications
CORNEAL ABRASION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
CORONARY ARTERY REOCCLUSION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
CORONARY ARTERY RESTENOSIS
2.3%
30/1296 • 5 years
1.6%
21/1308 • 5 years
Injury, poisoning and procedural complications
CRANIOCEREBRAL INJURY
0.23%
3/1296 • 5 years
0.15%
2/1308 • 5 years
Injury, poisoning and procedural complications
CYSTITIS RADIATION
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Injury, poisoning and procedural complications
DEPRESSION POSTOPERATIVE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
DRUG ADMINISTRATION ERROR
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
EAR INJURY
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
EPICONDYLITIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
EXCORIATION
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Injury, poisoning and procedural complications
EXPOSURE TO TOXIC AGENT
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
EYE PENETRATION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
FACIAL BONES FRACTURE
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
FALL
1.3%
17/1296 • 5 years
1.6%
21/1308 • 5 years
Injury, poisoning and procedural complications
FEMORAL NECK FRACTURE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
FEMUR FRACTURE
0.23%
3/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
FIBULA FRACTURE
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Injury, poisoning and procedural complications
FOOT FRACTURE
0.15%
2/1296 • 5 years
0.46%
6/1308 • 5 years
Injury, poisoning and procedural complications
FOREARM FRACTURE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
FOREIGN BODY IN EYE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
FRACTURE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
GASTROINTESTINAL DISORDER POSTOPERATIVE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
GASTROINTESTINAL STOMA COMPLICATION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
HAEMATURIA TRAUMATIC
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
HAND FRACTURE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
HEAD INJURY
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
HEAT EXHAUSTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
HEAT STROKE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
HIP FRACTURE
0.15%
2/1296 • 5 years
0.15%
2/1308 • 5 years
Injury, poisoning and procedural complications
HUMERUS FRACTURE
0.31%
4/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
IN-STENT ARTERIAL RESTENOSIS
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
IN-STENT CORONARY ARTERY RESTENOSIS
0.62%
8/1296 • 5 years
1.5%
19/1308 • 5 years
Injury, poisoning and procedural complications
INCISION SITE PAIN
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
INCISIONAL HERNIA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
INCORRECT DOSE ADMINISTERED
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
INJURY
0.23%
3/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
INTENTIONAL OVERDOSE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
JOINT DISLOCATION
0.00%
0/1296 • 5 years
0.23%
3/1308 • 5 years
Injury, poisoning and procedural complications
JOINT INJURY
0.23%
3/1296 • 5 years
0.38%
5/1308 • 5 years
Injury, poisoning and procedural complications
LACERATION
0.85%
11/1296 • 5 years
0.84%
11/1308 • 5 years
Injury, poisoning and procedural complications
LIGAMENT RUPTURE
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
LIGAMENT SPRAIN
0.46%
6/1296 • 5 years
0.46%
6/1308 • 5 years
Injury, poisoning and procedural complications
LIMB INJURY
0.23%
3/1296 • 5 years
0.31%
4/1308 • 5 years
Injury, poisoning and procedural complications
LUMBAR VERTEBRAL FRACTURE
0.15%
2/1296 • 5 years
0.15%
2/1308 • 5 years
Injury, poisoning and procedural complications
MENISCUS LESION
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Injury, poisoning and procedural complications
MOUTH INJURY
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Injury, poisoning and procedural complications
MULTIPLE FRACTURES
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
MULTIPLE INJURIES
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
MUSCLE RUPTURE
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
MUSCLE STRAIN
0.15%
2/1296 • 5 years
0.38%
5/1308 • 5 years
Injury, poisoning and procedural complications
OVERDOSE
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
PATELLA FRACTURE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
PELVIC FRACTURE
0.00%
0/1296 • 5 years
0.23%
3/1308 • 5 years
Injury, poisoning and procedural complications
PELVIC ORGAN INJURY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
PERIPROSTHETIC FRACTURE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
PLAQUE SHIFT
0.23%
3/1296 • 5 years
0.31%
4/1308 • 5 years
Injury, poisoning and procedural complications
POISONING
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
POISONING DELIBERATE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
POST LAMINECTOMY SYNDROME
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
POST PROCEDURAL BILE LEAK
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
POST PROCEDURAL COMPLICATION
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
POST PROCEDURAL DISCOMFORT
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
POST PROCEDURAL HAEMATOMA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
POST PROCEDURAL HAEMATURIA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
POST PROCEDURAL HAEMORRHAGE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
POST PROCEDURAL MYOCARDIAL INFARCTION
1.5%
20/1296 • 5 years
0.99%
13/1308 • 5 years
Injury, poisoning and procedural complications
POST PROCEDURAL OEDEMA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
POST-TRAUMATIC PAIN
0.62%
8/1296 • 5 years
0.54%
7/1308 • 5 years
Injury, poisoning and procedural complications
POSTOPERATIVE FEVER
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
POSTOPERATIVE HERNIA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
POSTOPERATIVE ILEUS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
POSTOPERATIVE RESPIRATORY DISTRESS
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
PROCEDURAL COMPLICATION
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
PROCEDURAL DIZZINESS
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
PROCEDURAL HAEMORRHAGE
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
PROCEDURAL HEADACHE
0.23%
3/1296 • 5 years
0.31%
4/1308 • 5 years
Injury, poisoning and procedural complications
PROCEDURAL HYPERTENSION
0.39%
5/1296 • 5 years
0.38%
5/1308 • 5 years
Injury, poisoning and procedural complications
PROCEDURAL HYPOTENSION
0.77%
10/1296 • 5 years
0.15%
2/1308 • 5 years
Injury, poisoning and procedural complications
PROCEDURAL NAUSEA
0.62%
8/1296 • 5 years
0.46%
6/1308 • 5 years
Injury, poisoning and procedural complications
PROCEDURAL PAIN
1.2%
16/1296 • 5 years
1.1%
15/1308 • 5 years
Injury, poisoning and procedural complications
PROCEDURAL VOMITING
0.08%
1/1296 • 5 years
0.23%
3/1308 • 5 years
Injury, poisoning and procedural complications
RADIUS FRACTURE
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
RIB FRACTURE
0.54%
7/1296 • 5 years
0.23%
3/1308 • 5 years
Injury, poisoning and procedural complications
ROAD TRAFFIC ACCIDENT
0.46%
6/1296 • 5 years
0.46%
6/1308 • 5 years
Injury, poisoning and procedural complications
SEROMA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
SKELETAL INJURY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
SKULL FRACTURE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
SPINAL COLUMN INJURY
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
SPINAL COMPRESSION FRACTURE
0.39%
5/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
SPINAL FRACTURE
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
STAB WOUND
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
SUBCUTANEOUS HAEMATOMA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
SUBDURAL HAEMATOMA
0.08%
1/1296 • 5 years
0.23%
3/1308 • 5 years
Injury, poisoning and procedural complications
SUBDURAL HAEMORRHAGE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
SUTURE RUPTURE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
TENDON RUPTURE
0.15%
2/1296 • 5 years
0.23%
3/1308 • 5 years
Injury, poisoning and procedural complications
THERMAL BURN
0.23%
3/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
THORACIC VERTEBRAL FRACTURE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
TOOTH FRACTURE
0.08%
1/1296 • 5 years
0.23%
3/1308 • 5 years
Injury, poisoning and procedural complications
TRAUMATIC ARTHRITIS
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
TRAUMATIC HAEMATOMA
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Injury, poisoning and procedural complications
TRAUMATIC HAEMORRHAGE
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
TRAUMATIC INTRACRANIAL HAEMORRHAGE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Injury, poisoning and procedural complications
TRAUMATIC LUNG INJURY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
ULNA FRACTURE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
UPPER LIMB FRACTURE
0.08%
1/1296 • 5 years
0.23%
3/1308 • 5 years
Injury, poisoning and procedural complications
URINARY RETENTION POSTOPERATIVE
0.23%
3/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
VASCULAR GRAFT COMPLICATION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
VASCULAR GRAFT OCCLUSION
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Injury, poisoning and procedural complications
VASCULAR PSEUDOANEURYSM
0.54%
7/1296 • 5 years
0.61%
8/1308 • 5 years
Injury, poisoning and procedural complications
WOUND COMPLICATION
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
WOUND DEHISCENCE
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
WOUND HAEMORRHAGE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Injury, poisoning and procedural complications
WRIST FRACTURE
0.08%
1/1296 • 5 years
0.38%
5/1308 • 5 years
Investigations
ALANINE AMINOTRANSFERASE INCREASED
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Investigations
ANGIOGRAM
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Investigations
ARTERIAL BRUIT
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Investigations
ARTERIOGRAM CORONARY
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Investigations
ARTERIOGRAM CORONARY ABNORMAL
0.08%
1/1296 • 5 years
0.31%
4/1308 • 5 years
Investigations
BLOOD CHOLESTEROL DECREASED
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Investigations
BLOOD CHOLESTEROL INCREASED
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Investigations
BLOOD CREATINE PHOSPHOKINASE INCREASED
1.4%
18/1296 • 5 years
1.5%
20/1308 • 5 years
Investigations
BLOOD CREATINE PHOSPHOKINASE MB ABNORMAL
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Investigations
BLOOD CREATINE PHOSPHOKINASE MB DECREASED
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Investigations
BLOOD CREATINE PHOSPHOKINASE MB INCREASED
5.2%
68/1296 • 5 years
4.5%
59/1308 • 5 years
Investigations
BLOOD CREATININE INCREASED
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Investigations
BLOOD GLUCOSE DECREASED
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Investigations
BLOOD GLUCOSE INCREASED
0.31%
4/1296 • 5 years
0.31%
4/1308 • 5 years
Investigations
BLOOD LACTIC ACID INCREASED
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Investigations
BLOOD MAGNESIUM DECREASED
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Investigations
BLOOD POTASSIUM DECREASED
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Investigations
BLOOD PRESSURE DECREASED
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Investigations
BLOOD PRESSURE INCREASED
0.93%
12/1296 • 5 years
0.46%
6/1308 • 5 years
Investigations
BLOOD PRESSURE SYSTOLIC DECREASED
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Investigations
BLOOD PRESSURE SYSTOLIC INCREASED
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Investigations
BLOOD TESTOSTERONE DECREASED
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Investigations
BLOOD TRIGLYCERIDES INCREASED
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Investigations
BLOOD URIC ACID INCREASED
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Investigations
BLOOD URINE PRESENT
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Investigations
BODY TEMPERATURE INCREASED
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Investigations
CARDIAC ENZYMES INCREASED
11.5%
149/1296 • 5 years
11.5%
150/1308 • 5 years
Investigations
CARDIAC IMAGING PROCEDURE ABNORMAL
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Investigations
CARDIAC MURMUR
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Investigations
CARDIAC STRESS TEST ABNORMAL
0.23%
3/1296 • 5 years
0.38%
5/1308 • 5 years
Investigations
CAROTID BRUIT
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Investigations
CATHETERISATION CARDIAC
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Investigations
COMPUTERISED TOMOGRAM THORAX ABNORMAL
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Investigations
CORONAVIRUS TEST POSITIVE
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Investigations
EJECTION FRACTION DECREASED
0.31%
4/1296 • 5 years
0.23%
3/1308 • 5 years
Investigations
ELECTROCARDIOGRAM ABNORMAL
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Investigations
ELECTROCARDIOGRAM ST SEGMENT ELEVATION
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Investigations
FEMORAL BRUIT
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Investigations
FIBRIN D DIMER INCREASED
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Investigations
GLYCOSYLATED HAEMOGLOBIN INCREASED
0.00%
0/1296 • 5 years
0.23%
3/1308 • 5 years
Investigations
HAEMOGLOBIN DECREASED
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Investigations
HEART RATE INCREASED
0.15%
2/1296 • 5 years
0.15%
2/1308 • 5 years
Investigations
HEART RATE IRREGULAR
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Investigations
HEPATIC ENZYME INCREASED
0.15%
2/1296 • 5 years
0.23%
3/1308 • 5 years
Investigations
INFLUENZA A VIRUS TEST POSITIVE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Investigations
LEFT VENTRICULAR END-DIASTOLIC PRESSURE INCREASED
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Investigations
LIVER FUNCTION TEST ABNORMAL
0.23%
3/1296 • 5 years
0.23%
3/1308 • 5 years
Investigations
LIVER SCAN ABNORMAL
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Investigations
LOW DENSITY LIPOPROTEIN INCREASED
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Investigations
LYMPHOCYTE COUNT INCREASED
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Investigations
MEAN CELL VOLUME ABNORMAL
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Investigations
N-TERMINAL PROHORMONE BRAIN NATRIURETIC PEPTIDE INCREASED
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Investigations
OCCULT BLOOD POSITIVE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Investigations
OESOPHAGOGASTRODUODENOSCOPY ABNORMAL
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Investigations
OXYGEN SATURATION DECREASED
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Investigations
PLATELET COUNT DECREASED
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Investigations
POSITRON EMISSION TOMOGRAM ABNORMAL
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Investigations
PROSTATIC SPECIFIC ANTIGEN INCREASED
0.08%
1/1296 • 5 years
0.23%
3/1308 • 5 years
Investigations
SCAN MYOCARDIAL PERFUSION ABNORMAL
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Investigations
STRESS ECHOCARDIOGRAM ABNORMAL
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Investigations
TRANSAMINASES INCREASED
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Investigations
TROPONIN I INCREASED
0.62%
8/1296 • 5 years
1.1%
14/1308 • 5 years
Investigations
TROPONIN INCREASED
8.4%
109/1296 • 5 years
6.6%
86/1308 • 5 years
Investigations
TROPONIN T INCREASED
1.1%
14/1296 • 5 years
0.92%
12/1308 • 5 years
Investigations
ULTRASOUND THYROID ABNORMAL
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Investigations
WEIGHT DECREASED
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Investigations
WEIGHT INCREASED
0.15%
2/1296 • 5 years
0.15%
2/1308 • 5 years
Investigations
WHITE BLOOD CELL COUNT DECREASED
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Metabolism and nutrition disorders
CARBOHYDRATE INTOLERANCE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Metabolism and nutrition disorders
DECREASED APPETITE
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Metabolism and nutrition disorders
DEHYDRATION
0.62%
8/1296 • 5 years
0.54%
7/1308 • 5 years
Metabolism and nutrition disorders
DIABETES MELLITUS
0.62%
8/1296 • 5 years
0.76%
10/1308 • 5 years
Metabolism and nutrition disorders
DIABETES MELLITUS INADEQUATE CONTROL
0.39%
5/1296 • 5 years
0.15%
2/1308 • 5 years
Metabolism and nutrition disorders
DIABETIC KETOACIDOSIS
0.15%
2/1296 • 5 years
0.38%
5/1308 • 5 years
Metabolism and nutrition disorders
FAILURE TO THRIVE
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Metabolism and nutrition disorders
FLUID OVERLOAD
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Metabolism and nutrition disorders
GLUCOSE TOLERANCE IMPAIRED
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Metabolism and nutrition disorders
GOUT
0.77%
10/1296 • 5 years
0.54%
7/1308 • 5 years
Metabolism and nutrition disorders
HYPERAMMONAEMIA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Metabolism and nutrition disorders
HYPERCALCAEMIA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Metabolism and nutrition disorders
HYPERCHOLESTEROLAEMIA
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Metabolism and nutrition disorders
HYPERGLYCAEMIA
0.54%
7/1296 • 5 years
0.31%
4/1308 • 5 years
Metabolism and nutrition disorders
HYPERKALAEMIA
0.39%
5/1296 • 5 years
0.00%
0/1308 • 5 years
Metabolism and nutrition disorders
HYPERLIPIDAEMIA
0.15%
2/1296 • 5 years
0.31%
4/1308 • 5 years
Metabolism and nutrition disorders
HYPERTRIGLYCERIDAEMIA
0.23%
3/1296 • 5 years
0.08%
1/1308 • 5 years
Metabolism and nutrition disorders
HYPERURICAEMIA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Metabolism and nutrition disorders
HYPOGLYCAEMIA
0.54%
7/1296 • 5 years
0.61%
8/1308 • 5 years
Metabolism and nutrition disorders
HYPOKALAEMIA
0.00%
0/1296 • 5 years
0.31%
4/1308 • 5 years
Metabolism and nutrition disorders
HYPOMAGNESAEMIA
0.08%
1/1296 • 5 years
0.23%
3/1308 • 5 years
Metabolism and nutrition disorders
HYPONATRAEMIA
0.00%
0/1296 • 5 years
0.46%
6/1308 • 5 years
Metabolism and nutrition disorders
HYPOVITAMINOSIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Metabolism and nutrition disorders
HYPOVOLAEMIA
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Metabolism and nutrition disorders
IMPAIRED FASTING GLUCOSE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Metabolism and nutrition disorders
IRON DEFICIENCY
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Metabolism and nutrition disorders
KETOACIDOSIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Metabolism and nutrition disorders
LACTIC ACIDOSIS
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Metabolism and nutrition disorders
MALNUTRITION
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Metabolism and nutrition disorders
METABOLIC ACIDOSIS
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Metabolism and nutrition disorders
METABOLIC SYNDROME
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Metabolism and nutrition disorders
OBESITY
0.08%
1/1296 • 5 years
0.38%
5/1308 • 5 years
Metabolism and nutrition disorders
TYPE 1 DIABETES MELLITUS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Metabolism and nutrition disorders
TYPE 2 DIABETES MELLITUS
0.39%
5/1296 • 5 years
0.38%
5/1308 • 5 years
Metabolism and nutrition disorders
VITAMIN B12 DEFICIENCY
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Metabolism and nutrition disorders
VITAMIN D DEFICIENCY
0.15%
2/1296 • 5 years
0.15%
2/1308 • 5 years
Musculoskeletal and connective tissue disorders
ARTHRALGIA
2.9%
37/1296 • 5 years
2.0%
26/1308 • 5 years
Musculoskeletal and connective tissue disorders
ARTHRITIS
0.77%
10/1296 • 5 years
0.54%
7/1308 • 5 years
Musculoskeletal and connective tissue disorders
ARTHROPATHY
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Musculoskeletal and connective tissue disorders
BACK PAIN
2.7%
35/1296 • 5 years
3.1%
40/1308 • 5 years
Musculoskeletal and connective tissue disorders
BONE PAIN
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Musculoskeletal and connective tissue disorders
BURSITIS
0.23%
3/1296 • 5 years
0.15%
2/1308 • 5 years
Musculoskeletal and connective tissue disorders
CERVICAL SPINAL STENOSIS
0.15%
2/1296 • 5 years
0.31%
4/1308 • 5 years
Musculoskeletal and connective tissue disorders
CHONDROCALCINOSIS PYROPHOSPHATE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Musculoskeletal and connective tissue disorders
CHONDROMALACIA
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Musculoskeletal and connective tissue disorders
CHONDROSIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Musculoskeletal and connective tissue disorders
COSTOCHONDRITIS
0.08%
1/1296 • 5 years
0.31%
4/1308 • 5 years
Musculoskeletal and connective tissue disorders
DUPUYTREN'S CONTRACTURE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Musculoskeletal and connective tissue disorders
EXOSTOSIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Musculoskeletal and connective tissue disorders
FACET JOINT SYNDROME
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Musculoskeletal and connective tissue disorders
FEMOROACETABULAR IMPINGEMENT
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Musculoskeletal and connective tissue disorders
FLANK PAIN
0.15%
2/1296 • 5 years
0.15%
2/1308 • 5 years
Musculoskeletal and connective tissue disorders
FOOT DEFORMITY
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Musculoskeletal and connective tissue disorders
GOUTY ARTHRITIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Musculoskeletal and connective tissue disorders
GROIN PAIN
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Musculoskeletal and connective tissue disorders
INTERVERTEBRAL DISC COMPRESSION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Musculoskeletal and connective tissue disorders
INTERVERTEBRAL DISC DEGENERATION
0.23%
3/1296 • 5 years
0.23%
3/1308 • 5 years
Musculoskeletal and connective tissue disorders
INTERVERTEBRAL DISC PROTRUSION
0.46%
6/1296 • 5 years
0.38%
5/1308 • 5 years
Musculoskeletal and connective tissue disorders
JOINT EFFUSION
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Musculoskeletal and connective tissue disorders
JOINT STIFFNESS
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Musculoskeletal and connective tissue disorders
JOINT SWELLING
0.46%
6/1296 • 5 years
0.31%
4/1308 • 5 years
Musculoskeletal and connective tissue disorders
LIMB DISCOMFORT
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Musculoskeletal and connective tissue disorders
LUMBAR SPINAL STENOSIS
0.31%
4/1296 • 5 years
0.38%
5/1308 • 5 years
Musculoskeletal and connective tissue disorders
MONARTHRITIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Musculoskeletal and connective tissue disorders
MUSCLE ATROPHY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Musculoskeletal and connective tissue disorders
MUSCLE NECROSIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Musculoskeletal and connective tissue disorders
MUSCLE SPASMS
0.85%
11/1296 • 5 years
0.84%
11/1308 • 5 years
Musculoskeletal and connective tissue disorders
MUSCLE TIGHTNESS
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Musculoskeletal and connective tissue disorders
MUSCLE TWITCHING
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Musculoskeletal and connective tissue disorders
MUSCULAR WEAKNESS
0.62%
8/1296 • 5 years
0.46%
6/1308 • 5 years
Musculoskeletal and connective tissue disorders
MUSCULOSKELETAL CHEST PAIN
0.93%
12/1296 • 5 years
1.3%
17/1308 • 5 years
Musculoskeletal and connective tissue disorders
MUSCULOSKELETAL DISCOMFORT
0.23%
3/1296 • 5 years
0.31%
4/1308 • 5 years
Musculoskeletal and connective tissue disorders
MUSCULOSKELETAL PAIN
2.0%
26/1296 • 5 years
2.1%
27/1308 • 5 years
Musculoskeletal and connective tissue disorders
MUSCULOSKELETAL STIFFNESS
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Musculoskeletal and connective tissue disorders
MYALGIA
1.9%
24/1296 • 5 years
1.5%
19/1308 • 5 years
Musculoskeletal and connective tissue disorders
MYOPATHY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Musculoskeletal and connective tissue disorders
NECK PAIN
0.62%
8/1296 • 5 years
0.61%
8/1308 • 5 years
Musculoskeletal and connective tissue disorders
NEUROPATHIC ARTHROPATHY
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Musculoskeletal and connective tissue disorders
RHEUMATOID ARTHRITIS
0.00%
0/1296 • 5 years
0.31%
4/1308 • 5 years
Musculoskeletal and connective tissue disorders
ROTATOR CUFF SYNDROME
0.93%
12/1296 • 5 years
0.76%
10/1308 • 5 years
Musculoskeletal and connective tissue disorders
SACROILIITIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Musculoskeletal and connective tissue disorders
SCLERODERMA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Musculoskeletal and connective tissue disorders
SENILE ANKYLOSING VERTEBRAL HYPEROSTOSIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Musculoskeletal and connective tissue disorders
SPINAL COLUMN STENOSIS
0.23%
3/1296 • 5 years
0.23%
3/1308 • 5 years
Musculoskeletal and connective tissue disorders
SPINAL DISORDER
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Musculoskeletal and connective tissue disorders
SPINAL OSTEOARTHRITIS
0.31%
4/1296 • 5 years
0.54%
7/1308 • 5 years
Musculoskeletal and connective tissue disorders
SPONDYLOLISTHESIS
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Musculoskeletal and connective tissue disorders
SYNOVIAL CYST
0.23%
3/1296 • 5 years
0.08%
1/1308 • 5 years
Musculoskeletal and connective tissue disorders
TENDONITIS
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Musculoskeletal and connective tissue disorders
TENOSYNOVITIS STENOSANS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Musculoskeletal and connective tissue disorders
TRIGGER FINGER
0.15%
2/1296 • 5 years
0.38%
5/1308 • 5 years
Musculoskeletal and connective tissue disorders
VERTEBRAL FORAMINAL STENOSIS
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
ACUTE MYELOID LEUKAEMIA
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
ACUTE PROMYELOCYTIC LEUKAEMIA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
ADENOCARCINOMA
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
ADENOCARCINOMA PANCREAS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-CELL LYMPHOMA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-CELL LYMPHOMA STAGE I
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-CELL LYMPHOMA STAGE IV
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BASAL CELL CARCINOMA
0.46%
6/1296 • 5 years
0.61%
8/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BENIGN BREAST NEOPLASM
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BENIGN NEOPLASM OF BLADDER
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BENIGN SOFT TISSUE NEOPLASM
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BILE DUCT CANCER
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BLADDER CANCER
0.46%
6/1296 • 5 years
0.31%
4/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BLADDER NEOPLASM
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BOWEN'S DISEASE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BREAST CANCER
0.31%
4/1296 • 5 years
0.38%
5/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BREAST CANCER IN SITU
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BREAST CANCER STAGE II
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BRONCHIAL CARCINOMA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
CHRONIC LYMPHOCYTIC LEUKAEMIA
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
COLON ADENOMA
0.46%
6/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
COLON CANCER
0.46%
6/1296 • 5 years
0.38%
5/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
ENDOMETRIAL CANCER
0.15%
2/1296 • 5 years
0.15%
2/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
ENDOMETRIAL CANCER METASTATIC
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
FIBROMA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
GASTROINTESTINAL STROMAL TUMOUR
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MELANOCYTIC NAEVUS
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
HEPATIC NEOPLASM
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
HEPATIC NEOPLASM MALIGNANT
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
HEPATIC NEOPLASM MALIGNANT RECURRENT
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
INTESTINAL ADENOCARCINOMA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LARYNGEAL CANCER
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LIPOMA
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LUNG ADENOCARCINOMA
0.15%
2/1296 • 5 years
0.15%
2/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LUNG ADENOCARCINOMA METASTATIC
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LUNG CANCER METASTATIC
0.23%
3/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LUNG CARCINOMA CELL TYPE UNSPECIFIED STAGE IV
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LUNG NEOPLASM
0.46%
6/1296 • 5 years
0.23%
3/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LUNG NEOPLASM MALIGNANT
0.54%
7/1296 • 5 years
0.31%
4/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LUNG SQUAMOUS CELL CARCINOMA STAGE UNSPECIFIED
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LYMPHOMA
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MALIGNANT GLIOMA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MALIGNANT MELANOMA
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MALIGNANT MELANOMA IN SITU
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MALIGNANT PLEURAL EFFUSION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MANTLE CELL LYMPHOMA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MENINGIOMA
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
METASTASES TO CENTRAL NERVOUS SYSTEM
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
METASTASES TO LIVER
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
METASTATIC MALIGNANT MELANOMA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
METASTATIC NEOPLASM
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
METASTATIC RENAL CELL CARCINOMA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MUELLER'S MIXED TUMOUR
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MULTIPLE MYELOMA
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MYELODYSPLASTIC SYNDROME
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MYELOFIBROSIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
NEOPLASM MALIGNANT
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
NEOPLASM OF APPENDIX
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
NEOPLASM SKIN
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
NEUROENDOCRINE CARCINOMA METASTATIC
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
NON-HODGKIN'S LYMPHOMA
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
NON-SMALL CELL LUNG CANCER
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
OESOPHAGEAL CARCINOMA
0.08%
1/1296 • 5 years
0.23%
3/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
OROPHARYNGEAL CANCER STAGE UNSPECIFIED
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
OVARIAN CANCER METASTATIC
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
OVARIAN CANCER STAGE III
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
OVARIAN NEOPLASM
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PANCREATIC CARCINOMA
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PANCREATIC CARCINOMA METASTATIC
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PANCREATIC NEUROENDOCRINE TUMOUR
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PARATHYROID TUMOUR BENIGN
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PERITONEAL CARCINOMA METASTATIC
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PHAEOCHROMOCYTOMA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PITUITARY TUMOUR BENIGN
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PLASMACYTOMA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PLEURAL MESOTHELIOMA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PLEURAL MESOTHELIOMA MALIGNANT
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PROSTATE CANCER
0.69%
9/1296 • 5 years
0.61%
8/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PROSTATE CANCER METASTATIC
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
RECTAL ADENOMA
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
RECTAL CANCER
0.23%
3/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
RENAL CANCER
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
RENAL CELL CARCINOMA
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SALIVARY GLAND CANCER
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SALIVARY GLAND NEOPLASM
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SEBORRHOEIC KERATOSIS
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SKIN CANCER
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SMALL CELL LUNG CANCER STAGE UNSPECIFIED
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SQUAMOUS CELL CARCINOMA
0.15%
2/1296 • 5 years
0.23%
3/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SQUAMOUS CELL CARCINOMA OF SKIN
0.00%
0/1296 • 5 years
0.31%
4/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
THYROID CANCER
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
THYROID NEOPLASM
0.00%
0/1296 • 5 years
0.23%
3/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
TRACHEAL CANCER
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
TRANSITIONAL CELL CARCINOMA
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
URETERIC CANCER RECURRENT
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
AMNESIA
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
APHASIA
0.08%
1/1296 • 5 years
0.23%
3/1308 • 5 years
Nervous system disorders
BASAL GANGLIA INFARCTION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
BASILAR ARTERY STENOSIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
BRAIN INJURY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
BRAIN MASS
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Nervous system disorders
BRAIN STEM INFARCTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
CAROTID ARTERIOSCLEROSIS
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
CAROTID ARTERY DISEASE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
CAROTID ARTERY OCCLUSION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
CAROTID ARTERY STENOSIS
0.93%
12/1296 • 5 years
0.76%
10/1308 • 5 years
Nervous system disorders
CARPAL TUNNEL SYNDROME
0.62%
8/1296 • 5 years
0.69%
9/1308 • 5 years
Nervous system disorders
CENTRAL NERVOUS SYSTEM LESION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
CEREBELLAR ATROPHY
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
CEREBELLAR INFARCTION
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Nervous system disorders
CEREBRAL HAEMORRHAGE
0.15%
2/1296 • 5 years
0.23%
3/1308 • 5 years
Nervous system disorders
CEREBRAL INFARCTION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
CEREBRAL SMALL VESSEL ISCHAEMIC DISEASE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
CEREBROVASCULAR ACCIDENT
1.2%
15/1296 • 5 years
1.8%
23/1308 • 5 years
Nervous system disorders
CEREBROVASCULAR DISORDER
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
CERVICAL CORD COMPRESSION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
CERVICAL MYELOPATHY
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
CERVICOBRACHIAL SYNDROME
0.23%
3/1296 • 5 years
0.23%
3/1308 • 5 years
Nervous system disorders
CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
COGNITIVE DISORDER
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
COMPLICATED MIGRAINE
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
CONVULSION
0.31%
4/1296 • 5 years
0.15%
2/1308 • 5 years
Nervous system disorders
CRANIAL NERVE DISORDER
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
CUBITAL TUNNEL SYNDROME
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
DEMENTIA
0.15%
2/1296 • 5 years
0.15%
2/1308 • 5 years
Nervous system disorders
DEMENTIA ALZHEIMER'S TYPE
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
DEPRESSED LEVEL OF CONSCIOUSNESS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
DIABETIC NEUROPATHY
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
DIZZINESS
5.7%
74/1296 • 5 years
5.5%
72/1308 • 5 years
Nervous system disorders
DIZZINESS EXERTIONAL
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
DIZZINESS POSTURAL
1.1%
14/1296 • 5 years
0.46%
6/1308 • 5 years
Nervous system disorders
DRUG WITHDRAWAL HEADACHE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
DYSARTHRIA
0.08%
1/1296 • 5 years
0.23%
3/1308 • 5 years
Nervous system disorders
DYSGEUSIA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
EMBOLIC CEREBRAL INFARCTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
ENCEPHALOPATHY
0.54%
7/1296 • 5 years
0.15%
2/1308 • 5 years
Nervous system disorders
EPILEPSY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
ESSENTIAL TREMOR
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
FACIAL PARESIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
GRAND MAL CONVULSION
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
GUILLAIN-BARRE SYNDROME
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
HAEMORRHAGE INTRACRANIAL
0.08%
1/1296 • 5 years
0.23%
3/1308 • 5 years
Nervous system disorders
HAEMORRHAGIC STROKE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
HEAD DISCOMFORT
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
HEAD TITUBATION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
HEADACHE
1.8%
23/1296 • 5 years
2.1%
28/1308 • 5 years
Nervous system disorders
HEMIPARESIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
HYPERTONIA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
INTERCOSTAL NEURALGIA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
INTRACRANIAL ANEURYSM
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
INTRAVENTRICULAR HAEMORRHAGE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
ISCHAEMIC STROKE
0.08%
1/1296 • 5 years
0.23%
3/1308 • 5 years
Nervous system disorders
LACUNAR INFARCTION
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
LETHARGY
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Nervous system disorders
LOSS OF CONSCIOUSNESS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
LUMBAR RADICULOPATHY
0.00%
0/1296 • 5 years
0.23%
3/1308 • 5 years
Nervous system disorders
MEMORY IMPAIRMENT
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
METABOLIC ENCEPHALOPATHY
0.46%
6/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
MIGRAINE
0.39%
5/1296 • 5 years
0.23%
3/1308 • 5 years
Nervous system disorders
MIGRAINE WITH AURA
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
MONONEURITIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
MULTIPLE SCLEROSIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
MUSCLE CONTRACTIONS INVOLUNTARY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
NERVE COMPRESSION
0.15%
2/1296 • 5 years
0.15%
2/1308 • 5 years
Nervous system disorders
NEURALGIA
0.23%
3/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
NEURODEGENERATIVE DISORDER
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
NEUROPATHY PERIPHERAL
0.23%
3/1296 • 5 years
0.38%
5/1308 • 5 years
Nervous system disorders
PARAESTHESIA
2.2%
28/1296 • 5 years
1.8%
24/1308 • 5 years
Nervous system disorders
PARKINSON'S DISEASE
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Nervous system disorders
PARTIAL SEIZURES
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
PERIPHERAL SENSORY NEUROPATHY
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
PRESYNCOPE
1.0%
13/1296 • 5 years
0.76%
10/1308 • 5 years
Nervous system disorders
RADIAL NERVE COMPRESSION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
RADICULOPATHY
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
RESTLESS LEGS SYNDROME
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
SCIATICA
0.54%
7/1296 • 5 years
0.61%
8/1308 • 5 years
Nervous system disorders
SENSORY LOSS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
SOMNOLENCE
0.15%
2/1296 • 5 years
0.15%
2/1308 • 5 years
Nervous system disorders
SUBARACHNOID HAEMORRHAGE
0.00%
0/1296 • 5 years
0.31%
4/1308 • 5 years
Nervous system disorders
SYNCOPE
2.1%
27/1296 • 5 years
2.8%
36/1308 • 5 years
Nervous system disorders
TENSION HEADACHE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
TOXIC ENCEPHALOPATHY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
TRANSIENT ISCHAEMIC ATTACK
1.2%
16/1296 • 5 years
1.1%
14/1308 • 5 years
Nervous system disorders
TREMOR
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
TRIGEMINAL NEURALGIA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
TYPICAL AURA WITHOUT HEADACHE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
ULNAR TUNNEL SYNDROME
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Nervous system disorders
UNRESPONSIVE TO STIMULI
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
VERTEBRAL ARTERY STENOSIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Nervous system disorders
VIITH NERVE PARALYSIS
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Pregnancy, puerperium and perinatal conditions
ABORTION SPONTANEOUS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Psychiatric disorders
ALCOHOL WITHDRAWAL SYNDROME
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Psychiatric disorders
ANORGASMIA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Psychiatric disorders
ANXIETY
1.5%
20/1296 • 5 years
1.4%
18/1308 • 5 years
Psychiatric disorders
ANXIETY DISORDER DUE TO A GENERAL MEDICAL CONDITION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Psychiatric disorders
COMPLETED SUICIDE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Psychiatric disorders
CONFUSIONAL STATE
0.08%
1/1296 • 5 years
0.31%
4/1308 • 5 years
Psychiatric disorders
CONVERSION DISORDER
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Psychiatric disorders
DELIRIUM
0.23%
3/1296 • 5 years
0.15%
2/1308 • 5 years
Psychiatric disorders
DEPRESSION
0.62%
8/1296 • 5 years
0.92%
12/1308 • 5 years
Psychiatric disorders
DEPRESSION SUICIDAL
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Psychiatric disorders
DISORIENTATION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Psychiatric disorders
IMPAIRED SELF-CARE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Psychiatric disorders
INSOMNIA
0.54%
7/1296 • 5 years
0.54%
7/1308 • 5 years
Psychiatric disorders
INTENTIONAL SELF-INJURY
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Psychiatric disorders
MENTAL DISORDER DUE TO A GENERAL MEDICAL CONDITION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Psychiatric disorders
MENTAL STATUS CHANGES
0.54%
7/1296 • 5 years
0.46%
6/1308 • 5 years
Psychiatric disorders
PANIC ATTACK
0.15%
2/1296 • 5 years
0.31%
4/1308 • 5 years
Psychiatric disorders
PANIC DISORDER
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Psychiatric disorders
PERSONALITY DISORDER
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Psychiatric disorders
POST-TRAUMATIC AMNESTIC DISORDER
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Psychiatric disorders
PSYCHOGENIC PAIN DISORDER
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Psychiatric disorders
SLEEP DISORDER
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Psychiatric disorders
SOMATOFORM DISORDER
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Psychiatric disorders
STRESS
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Psychiatric disorders
SUICIDAL IDEATION
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Psychiatric disorders
SUICIDE ATTEMPT
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Psychiatric disorders
WITHDRAWAL SYNDROME
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Renal and urinary disorders
AZOTAEMIA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Renal and urinary disorders
BLADDER NECK OBSTRUCTION
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Renal and urinary disorders
BLADDER OBSTRUCTION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Renal and urinary disorders
BLADDER PERFORATION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Renal and urinary disorders
BLADDER PROLAPSE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Renal and urinary disorders
CALCULUS BLADDER
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Renal and urinary disorders
CALCULUS URETERIC
0.08%
1/1296 • 5 years
0.23%
3/1308 • 5 years
Renal and urinary disorders
CALCULUS URINARY
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Renal and urinary disorders
CYSTITIS HAEMORRHAGIC
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Renal and urinary disorders
DYSURIA
0.39%
5/1296 • 5 years
0.23%
3/1308 • 5 years
Renal and urinary disorders
HAEMATURIA
0.85%
11/1296 • 5 years
1.4%
18/1308 • 5 years
Renal and urinary disorders
HYDRONEPHROSIS
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Renal and urinary disorders
HYPERTONIC BLADDER
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Renal and urinary disorders
NEPHROLITHIASIS
1.1%
14/1296 • 5 years
1.1%
15/1308 • 5 years
Renal and urinary disorders
NOCTURIA
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Renal and urinary disorders
OBSTRUCTIVE UROPATHY
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Renal and urinary disorders
POLLAKIURIA
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Renal and urinary disorders
POLYURIA
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Renal and urinary disorders
PROTEINURIA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Renal and urinary disorders
RENAL ARTERY STENOSIS
0.15%
2/1296 • 5 years
0.31%
4/1308 • 5 years
Renal and urinary disorders
RENAL COLIC
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Renal and urinary disorders
RENAL CYST
0.23%
3/1296 • 5 years
0.15%
2/1308 • 5 years
Renal and urinary disorders
RENAL FAILURE
0.15%
2/1296 • 5 years
0.23%
3/1308 • 5 years
Renal and urinary disorders
RENAL FAILURE ACUTE
2.5%
32/1296 • 5 years
2.2%
29/1308 • 5 years
Renal and urinary disorders
RENAL FAILURE CHRONIC
0.08%
1/1296 • 5 years
0.38%
5/1308 • 5 years
Renal and urinary disorders
RENAL HAEMORRHAGE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Renal and urinary disorders
RENAL IMPAIRMENT
0.15%
2/1296 • 5 years
0.23%
3/1308 • 5 years
Renal and urinary disorders
RENAL MASS
0.23%
3/1296 • 5 years
0.08%
1/1308 • 5 years
Renal and urinary disorders
RENAL PAIN
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Renal and urinary disorders
URETERIC STENOSIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Renal and urinary disorders
URETHRAL MEATUS STENOSIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Renal and urinary disorders
URINARY BLADDER POLYP
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Renal and urinary disorders
URINARY HESITATION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Renal and urinary disorders
URINARY INCONTINENCE
0.15%
2/1296 • 5 years
0.31%
4/1308 • 5 years
Renal and urinary disorders
URINARY RETENTION
0.23%
3/1296 • 5 years
0.23%
3/1308 • 5 years
Renal and urinary disorders
URINARY TRACT OBSTRUCTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Renal and urinary disorders
URINE FLOW DECREASED
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Reproductive system and breast disorders
ACQUIRED HYDROCELE
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Reproductive system and breast disorders
ADNEXA UTERI MASS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Reproductive system and breast disorders
ATROPHIC VULVOVAGINITIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Reproductive system and breast disorders
BENIGN PROSTATIC HYPERPLASIA
0.69%
9/1296 • 5 years
0.84%
11/1308 • 5 years
Reproductive system and breast disorders
BREAST PAIN
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Reproductive system and breast disorders
CYSTOCELE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Reproductive system and breast disorders
ENDOMETRIAL HYPERPLASIA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Reproductive system and breast disorders
EPIDIDYMITIS
0.15%
2/1296 • 5 years
0.31%
4/1308 • 5 years
Reproductive system and breast disorders
ERECTILE DYSFUNCTION
0.54%
7/1296 • 5 years
0.15%
2/1308 • 5 years
Reproductive system and breast disorders
GENITAL PAIN
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Reproductive system and breast disorders
GENITAL SWELLING
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Reproductive system and breast disorders
GYNAECOMASTIA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Reproductive system and breast disorders
MENORRHAGIA
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Reproductive system and breast disorders
PELVIC PROLAPSE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Reproductive system and breast disorders
PENILE PAIN
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Reproductive system and breast disorders
PEYRONIE'S DISEASE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Reproductive system and breast disorders
PROSTATITIS
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Reproductive system and breast disorders
PROSTATOMEGALY
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Reproductive system and breast disorders
SCROTAL CYST
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Reproductive system and breast disorders
UTERINE OBSTRUCTION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Reproductive system and breast disorders
UTERINE POLYP
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Reproductive system and breast disorders
VAGINAL HAEMATOMA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Reproductive system and breast disorders
VAGINAL HAEMORRHAGE
0.00%
0/1296 • 5 years
0.31%
4/1308 • 5 years
Reproductive system and breast disorders
VAGINAL PROLAPSE
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Reproductive system and breast disorders
VULVAR DYSPLASIA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
ACQUIRED DIAPHRAGMATIC EVENTRATION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
ACUTE INTERSTITIAL PNEUMONITIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
ACUTE PULMONARY OEDEMA
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
ACUTE RESPIRATORY DISTRESS SYNDROME
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
ACUTE RESPIRATORY FAILURE
1.2%
15/1296 • 5 years
1.4%
18/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
ASPIRATION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
ASTHMA
0.77%
10/1296 • 5 years
0.31%
4/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
ATELECTASIS
0.23%
3/1296 • 5 years
0.46%
6/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
BRONCHITIS CHRONIC
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
BRONCHOSPASM
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
2.1%
27/1296 • 5 years
1.7%
22/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
CHRONIC RESPIRATORY FAILURE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
COUGH
1.4%
18/1296 • 5 years
2.4%
32/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
DIAPHRAGMATIC PARALYSIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
DYSPNOEA
12.3%
159/1296 • 5 years
12.8%
167/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
DYSPNOEA AT REST
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
DYSPNOEA EXERTIONAL
4.5%
58/1296 • 5 years
5.0%
66/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
EMPHYSEMA
0.31%
4/1296 • 5 years
0.00%
0/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
EPISTAXIS
1.6%
21/1296 • 5 years
1.2%
16/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
HAEMOPTYSIS
0.15%
2/1296 • 5 years
0.23%
3/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
HAEMOTHORAX
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
HICCUPS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
HYPOXIA
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
INTERSTITIAL LUNG DISEASE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
LUNG DISORDER
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
LUNG INFILTRATION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
NASAL CONGESTION
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
NASAL SEPTUM DEVIATION
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
NASAL TURBINATE HYPERTROPHY
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
OBSTRUCTIVE AIRWAYS DISORDER
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
OROPHARYNGEAL DISCOMFORT
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
OROPHARYNGEAL PAIN
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
PHARYNGEAL HYPERTROPHY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
PHARYNGEAL MASS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
PLEURAL EFFUSION
0.54%
7/1296 • 5 years
0.23%
3/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
PLEURAL FIBROSIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
PLEURITIC PAIN
0.23%
3/1296 • 5 years
0.31%
4/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
PNEUMONIA ASPIRATION
0.23%
3/1296 • 5 years
0.15%
2/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
PNEUMONITIS
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
PNEUMOTHORAX
0.23%
3/1296 • 5 years
0.15%
2/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
PRODUCTIVE COUGH
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
PULMONARY CONGESTION
0.00%
0/1296 • 5 years
0.23%
3/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
PULMONARY EMBOLISM
0.77%
10/1296 • 5 years
0.46%
6/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
PULMONARY FIBROSIS
0.15%
2/1296 • 5 years
0.15%
2/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
PULMONARY HYPERTENSION
0.31%
4/1296 • 5 years
0.23%
3/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
PULMONARY MASS
0.08%
1/1296 • 5 years
0.23%
3/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
PULMONARY OEDEMA
0.08%
1/1296 • 5 years
0.38%
5/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
PULMONARY TOXICITY
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
REFLUX LARYNGITIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
RESPIRATORY ALKALOSIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
RESPIRATORY ARREST
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
RESPIRATORY DISTRESS
0.23%
3/1296 • 5 years
0.08%
1/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
RESPIRATORY FAILURE
0.93%
12/1296 • 5 years
0.38%
5/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
RESTRICTIVE PULMONARY DISEASE
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
RHINITIS ALLERGIC
0.15%
2/1296 • 5 years
0.15%
2/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
SINUS CONGESTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
SLEEP APNOEA SYNDROME
0.46%
6/1296 • 5 years
0.99%
13/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
THROAT IRRITATION
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
THROAT TIGHTNESS
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
UPPER RESPIRATORY TRACT CONGESTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
VOCAL CORD POLYP
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Respiratory, thoracic and mediastinal disorders
WHEEZING
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Skin and subcutaneous tissue disorders
ACNE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Skin and subcutaneous tissue disorders
ACTINIC KERATOSIS
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Skin and subcutaneous tissue disorders
ALOPECIA
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Skin and subcutaneous tissue disorders
ANGIOEDEMA
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Skin and subcutaneous tissue disorders
COLD SWEAT
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Skin and subcutaneous tissue disorders
DECUBITUS ULCER
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Skin and subcutaneous tissue disorders
DERMAL CYST
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Skin and subcutaneous tissue disorders
DERMATITIS
0.15%
2/1296 • 5 years
0.15%
2/1308 • 5 years
Skin and subcutaneous tissue disorders
DERMATITIS CONTACT
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Skin and subcutaneous tissue disorders
DIGITAL ULCER
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Skin and subcutaneous tissue disorders
DRUG ERUPTION
0.77%
10/1296 • 5 years
0.46%
6/1308 • 5 years
Skin and subcutaneous tissue disorders
DRY GANGRENE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Skin and subcutaneous tissue disorders
ECCHYMOSIS
0.08%
1/1296 • 5 years
0.31%
4/1308 • 5 years
Skin and subcutaneous tissue disorders
ERYTHEMA
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Skin and subcutaneous tissue disorders
HYPERHIDROSIS
1.6%
21/1296 • 5 years
1.8%
23/1308 • 5 years
Skin and subcutaneous tissue disorders
INCREASED TENDENCY TO BRUISE
0.31%
4/1296 • 5 years
0.46%
6/1308 • 5 years
Skin and subcutaneous tissue disorders
INGROWING NAIL
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Skin and subcutaneous tissue disorders
LEUKOCYTOCLASTIC VASCULITIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Skin and subcutaneous tissue disorders
LICHEN SCLEROSUS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Skin and subcutaneous tissue disorders
LIVEDO RETICULARIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Skin and subcutaneous tissue disorders
NIGHT SWEATS
0.23%
3/1296 • 5 years
0.38%
5/1308 • 5 years
Skin and subcutaneous tissue disorders
PETECHIAE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Skin and subcutaneous tissue disorders
PRECANCEROUS SKIN LESION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Skin and subcutaneous tissue disorders
PRURITUS
0.31%
4/1296 • 5 years
0.15%
2/1308 • 5 years
Skin and subcutaneous tissue disorders
PRURITUS ALLERGIC
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Skin and subcutaneous tissue disorders
PSORIASIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Skin and subcutaneous tissue disorders
RASH
1.0%
13/1296 • 5 years
0.38%
5/1308 • 5 years
Skin and subcutaneous tissue disorders
RASH GENERALISED
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Skin and subcutaneous tissue disorders
RASH MACULAR
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Skin and subcutaneous tissue disorders
RASH PRURITIC
0.31%
4/1296 • 5 years
0.15%
2/1308 • 5 years
Skin and subcutaneous tissue disorders
SCAR PAIN
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Skin and subcutaneous tissue disorders
SKIN DISCOLOURATION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Skin and subcutaneous tissue disorders
SKIN FISSURES
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Skin and subcutaneous tissue disorders
SKIN LESION
0.15%
2/1296 • 5 years
0.23%
3/1308 • 5 years
Skin and subcutaneous tissue disorders
SKIN ULCER
0.23%
3/1296 • 5 years
0.31%
4/1308 • 5 years
Skin and subcutaneous tissue disorders
SWELLING FACE
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Skin and subcutaneous tissue disorders
SYSTEMIC LUPUS ERYTHEMATOSUS RASH
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Skin and subcutaneous tissue disorders
URTICARIA
0.39%
5/1296 • 5 years
0.15%
2/1308 • 5 years
Social circumstances
MENOPAUSE
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Social circumstances
PHYSICAL ASSAULT
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Social circumstances
TREATMENT NONCOMPLIANCE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Surgical and medical procedures
ABSCESS DRAINAGE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Surgical and medical procedures
AORTIC STENT INSERTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Surgical and medical procedures
BAKER'S CYST EXCISION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Surgical and medical procedures
CARDIAC PACEMAKER BATTERY REPLACEMENT
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Surgical and medical procedures
CATARACT OPERATION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Surgical and medical procedures
CORONARY ARTERIAL STENT INSERTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Surgical and medical procedures
FRACTURE REDUCTION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Surgical and medical procedures
HERNIA REPAIR
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Surgical and medical procedures
HIP ARTHROPLASTY
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Surgical and medical procedures
HYSTERECTOMY
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Surgical and medical procedures
IMPLANTABLE DEFIBRILLATOR INSERTION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Surgical and medical procedures
KNEE ARTHROPLASTY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Surgical and medical procedures
NASAL OPERATION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Surgical and medical procedures
NECK SURGERY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Surgical and medical procedures
PERCUTANEOUS CORONARY INTERVENTION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Surgical and medical procedures
ROTATOR CUFF REPAIR
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Surgical and medical procedures
SURGERY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Vascular disorders
ACCELERATED HYPERTENSION
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Vascular disorders
ANEURYSM
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Vascular disorders
AORTIC ANEURYSM
0.15%
2/1296 • 5 years
0.31%
4/1308 • 5 years
Vascular disorders
AORTIC DISSECTION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Vascular disorders
AORTIC INTRAMURAL HAEMATOMA
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Vascular disorders
AORTIC STENOSIS
0.31%
4/1296 • 5 years
0.31%
4/1308 • 5 years
Vascular disorders
ARTERIAL DISORDER
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Vascular disorders
ARTERIAL HAEMORRHAGE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Vascular disorders
ARTERIAL OCCLUSIVE DISEASE
0.08%
1/1296 • 5 years
0.08%
1/1308 • 5 years
Vascular disorders
ARTERIAL SPASM
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Vascular disorders
ARTERIAL THROMBOSIS LIMB
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Vascular disorders
ARTERIOSCLEROSIS
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Vascular disorders
ARTERIOVENOUS FISTULA
0.08%
1/1296 • 5 years
0.15%
2/1308 • 5 years
Vascular disorders
DEEP VEIN THROMBOSIS
0.54%
7/1296 • 5 years
0.46%
6/1308 • 5 years
Vascular disorders
EMBOLISM ARTERIAL
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Vascular disorders
ESSENTIAL HYOERTENSION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Vascular disorders
FEMORAL ARTERIAL STENOSIS
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Vascular disorders
FEMORAL ARTERY ANEURYSM
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Vascular disorders
FEMORAL ARTERY DISSECTION
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Vascular disorders
FEMORAL ARTERY OCCLUSION
0.15%
2/1296 • 5 years
0.15%
2/1308 • 5 years
Vascular disorders
HAEMATOMA
0.62%
8/1296 • 5 years
0.92%
12/1308 • 5 years
Vascular disorders
HAEMORRHAGE
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Vascular disorders
HOT FLUSH
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Vascular disorders
HYPERTENSION
4.2%
55/1296 • 5 years
5.3%
69/1308 • 5 years
Vascular disorders
HYPERTENSIVE CRISIS
1.0%
13/1296 • 5 years
0.84%
11/1308 • 5 years
Vascular disorders
HYPERTENSIVE EMERGENCY
0.15%
2/1296 • 5 years
0.15%
2/1308 • 5 years
Vascular disorders
HYPOTENSION
2.9%
38/1296 • 5 years
2.2%
29/1308 • 5 years
Vascular disorders
HYPOVOLAEMIC SHOCK
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Vascular disorders
ILIAC ARTERY OCCLUSION
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Vascular disorders
ILIAC ARTERY STENOSIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Vascular disorders
INTERMITTENT CLAUDICATION
0.77%
10/1296 • 5 years
0.46%
6/1308 • 5 years
Vascular disorders
INTRA-ABDOMINAL HAEMATOMA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Vascular disorders
ISCHAEMIC LIMB PAIN
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Vascular disorders
LERICHE SYNDROME
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Vascular disorders
LYMPHOEDEMA
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Vascular disorders
MACROANGIOPATHY
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Vascular disorders
MALIGNANT HYPERTENSION
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Vascular disorders
ORTHOSTATIC HYPOTENSION
0.62%
8/1296 • 5 years
0.54%
7/1308 • 5 years
Vascular disorders
PELVIC VENOUS THROMBOSIS
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Vascular disorders
PERIPHERAL ARTERIAL OCCLUSIVE DISEASE
0.69%
9/1296 • 5 years
1.2%
16/1308 • 5 years
Vascular disorders
PERIPHERAL COLDNESS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Vascular disorders
PERIPHERAL ISCHAEMIA
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Vascular disorders
PERIPHERAL VASCULAR DISORDER
0.39%
5/1296 • 5 years
0.46%
6/1308 • 5 years
Vascular disorders
REPERFUSION INJURY
0.15%
2/1296 • 5 years
0.15%
2/1308 • 5 years
Vascular disorders
SHOCK
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Vascular disorders
THROMBOPHLEBITIS
0.00%
0/1296 • 5 years
0.15%
2/1308 • 5 years
Vascular disorders
THROMBOPHLEBITIS SUPERFICIAL
0.00%
0/1296 • 5 years
0.23%
3/1308 • 5 years
Vascular disorders
THROMBOSIS
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Vascular disorders
VARICOSE VEIN
0.15%
2/1296 • 5 years
0.00%
0/1308 • 5 years
Vascular disorders
VASCULAR STENOSIS
0.00%
0/1296 • 5 years
0.08%
1/1308 • 5 years
Vascular disorders
VASOSPASM
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years
Vascular disorders
VENOUS INSUFFICIENCY
0.15%
2/1296 • 5 years
0.15%
2/1308 • 5 years
Vascular disorders
VENOUS RECANALISATION
0.08%
1/1296 • 5 years
0.00%
0/1308 • 5 years
Vascular disorders
VENOUS THROMBOSIS LIMB
0.15%
2/1296 • 5 years
0.08%
1/1308 • 5 years

Additional Information

Kelly A. Stockelman, PhD

Abbott Vascular

Phone: 720-951-8649

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place

Restriction type: LTE60